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resumo 
 
 
O coração saudável gera até 30% do seu ATP a partir da glicose. Em 
condições de lesão cardíaca e stress, o coração depende ainda mais da 
glicose como fonte de energia. A glicose é transportada para os cadiomiócitos 
por proteínas da família dos transportadores de glicose (GLUTs). As isoformas 
predominantes no miocárdio são GLUT1 e GLUT4. GLUT4 é a isoforma 
predominante no coração adulto e a sua deleção genética no coração está 
associada ao desenvolvimento de hipertrofia cardíaca. No coração fetal, a 
isoforma predominante é GLUT1, cuja expressão diminui no coração adulto em 
resposta a lesões do miocárdio e a stress. A neuregulina-1 (NRG1) é uma 
proteína envolvida no metabolismo da glicose e tem um papel benéfico na 
Hipertensão Arterial Pulmonar (HAP) e na hipertrofia do ventrículo direito (VD). 
Neste estudo, o principal objetivo foi estudar a correlação entre a expressão de 
GLUT1 e GLUT4 e de marcadores de HAP no VD, com recurso a um modelo 
animal de HAP. Também se avaliou o efeito do tratamento crónico com NRG1 
na expressão de GLUT1 e GLUT4 no VD de animais com insuficiência 
cardíaca (IC) associada a HAP. 
Ratos Wistar receberam aleatoriamente monocrotalina (MCT; 60mg /kg de 
peso corporal) ou veículo. Após 14 dias, os animais foram tratados 
aleatoriamente com NRG1 recombinante humana (rhNRG1; 40µg/kg de peso 
corporal/dia) ou com veículo. Durante o estudo 4 grupos foram formados: 
control (CTRL); CTRL+rhNRG1; MCT and MCT+rhNRG1. Decorridos 21 a 24 
dias e após avaliação hemodinâmica dos animais experimentais, procedeu-se 
à sua eutanásia e recolha de amostras tecidulares. 
Neste modelo animal de HAP, verificámos que a diminuição da fração de 
ejeção (FE) se correlaciona positivamente com o aumento da expressão de 
GLUT1 (p=0,0005) e com a diminuição da expressão de GLUT4 (p=0,0167) no 
VD. Também observámos correlação positiva (p<0,0001) entre o aumento da 
expressão de GLUT1 e do fator induzido por hipoxia-1 (HIF-1α). A redução da 
expressão de GLUT4 está correlacionada com o aumento da expressão do 
péptido natriurético cerebral (BNP) (p=0,0032) e da endotelina-1 (ET-1) 
(p=0,0006), dois marcadores de sobrecarga e hipertrofia. Verificámos o 
aumento da expressão de GLUT1 no VE do grupo MCT relativamente à sua 
expressão no grupo CTRL; no grupo MCT+rhNRG1 esses valores foram 
completamente revertidos para os valores do controlo. A expressão de GLUT4 
aumentou em todos os grupos de animais tratados com rhNRG1. 
No presente estudo, observámos que a expressão de GLUT1 está associada 
desenvolvimento de doença e que a expressão de GLUT4 é afetada pelo 
tratamento crónico com rhNRG1. A expressão de GLUT1 e GLUT4 está 
correlacionada com parâmetros de função cardíaca e marcadores de doença. 
O tratamento crónico com rhNRG1 atenua as alterações nos GLUTs 
observadas na HAP induzida por MCT. Assim, podemos concluir que os 
efeitos terapêuticos da rhNRG1 na HAP podem ser devidos, pelo menos em 
parte, à regulação da expressão de GLUT1 e GLUT4. 
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abstract 
 
The healthy heart generates up to 30% of its ATP from glucose. Under 
conditions of cardiac injury or stress, the heart relies even more heavily on 
glucose as a source of energy. Glucose is transported into the heart by 
members of the family of facilitative glucose transporters (GLUTs). The two 
major isoforms of glucose transporters in the myocardium are GLUT1 and 4. 
GLUT4 is the predominant GLUT expressed in the adult heart and its genetic 
ablation in the heart has been shown to result in marked cardiac hypertrophy. 
GLUT1 is a major GLUT expressed in the fetal heart but it decreases in the 
adult heart in response to myocardial injury or stress. Neuregulin-1 (NRG1), a 
protein that has been shown to play beneficial effects on Pulmonary Arterial 
Hypertension (PAH) and right ventricle (RV) hypertrophy, has also been 
associated with the regulation of glucose metabolism.  
In this study, we aimed to investigate the correlation between disease markers 
and the GLUT1 and 4 expressions in RV, in an animal model of PAH. We also 
aimed to evaluate the effect of chronic treatment with NRG1 on GLUT1 and 4 
expressions in the RV of animals with HF associated with PAH. 
Wistar rats randomly received 60mg/kg of monocrotaline (MCT) or vehicle. 
After 14 days, they were randomly treated with rhNRG1 (40μg/kg/day) or 
vehicle. The study resulted in 4 groups: control (CTRL); CTRL+rhNRG1; MCT 
and MCT+rhNRG1. Between the 21st and 24th days after administration of 
MCT, hemodynamic studies and sample collection were performed.  
In this animal model of PAH, we found that the decrease in ejection fraction 
(EF) correlates with increased GLUT1 expression (p=0.0005) and decrease in 
GLUT4 expression (p=0.0167) in RV. We also observed that increased GLUT1 
expression correlates with increased hypoxia-inducible factor 1-alpha (HIF1a) 
expression (p<0.0001). The decrease in GLUT4 expression was shown to 
correlate with increased brain natriuretic peptide (BNP) (p=0.0032) and 
endothelin 1 (ET1) (p=0.0006) expression, two markers of overload and 
hypertrophy. We observed an increase of GLUT1 RV expression in the MCT 
group compared to the CTRL group, in the MCT+rhNRG1 group these values 
were completely reverted. GLUT4 increased in all groups of animals treated 
with rhNRG1. 
In the present study, we observed that the expression of GLUT1 is associated 
with the development of the disease whereas GLUT4 is affected by chronic 
treatment with rhNRG1. The expression of GLUT1 and 4 correlates with 
parameters of cardiac function and with disease markers and chronic treatment 
with rhNRG1 attenuates the changes in GLUTs induced by MCT. So, we can 
conclude that the therapeutic effects of rhNRG1 in PAH might be due in part to 
the regulation of GLUT1 and 4 expressions. 
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I - INTRODUCTION 
1. Pulmonary arterial hypertension 
1.1. Etiology and definition 
Pulmonary arterial hypertension (PAH) is classified as an uncommon subgroup of pulmonary 
hypertension (PH) and it’s characterized by excessive vascular remodeling related to high arterial 
pressure and progressive overload of the right ventricle (RV), eventually leading to RV dysfunction 
and heart failure (HF)1. PAH can be an idiopathic (IPAH) disease, when no causes are determined, 
or hereditable (HPAH). However, PAH can also be induced by drugs or toxins or connected to other 
conditions, like connective tissue disease or congenital heart disease, and others2. 
PAH diagnosis is made by a right heart catheterization (RHC) exhibiting precapillary PH with a mean 
pulmonary arterial pressure (mPAP) of 25 mmHg or higher, a pulmonary capillary wedge pressure 
(PCWP) less than or equal to 15 mmHg and a pulmonary vascular resistance (PVR) higher than 3 
Wood units3. 
Patients with PAH can present several symptoms including shortness of breath, fatigue, a non-
productive cough, angina pectoris, syncope and peripheral oedema4. These symptoms are usually 
detected in late stage of PAH. To achieve an early diagnosis and treatment a better understanding 
of PAH is required3. 
1.2. Epidemiology and survival 
PAH is a rare disease with an estimated prevalence of 15–50 cases per million individuals5-8. The 
first systematic analysis of PAH epidemiology was performed by the NIH in 1981 and involved 32 
medical centers in the USA, with data on 187 patients with “primary pulmonary hypertension” 
(corresponding to idiopathic, heritable, and anorexigen-induced PAH in current classification)9,10. 
Since the original NIH registry in the USA, national and multinational PAH registries have reported 
baseline characteristics and outcome data on >10,000 patients with PAH5-7. These registries provide 
important insights into the evolving epidemiology of PAH11. 
The principal aim of the registries is the survival analysis. Before the era of targeted PAH therapy, 
data from the NIH registry showed a miserable prognosis for primary PH, with a median survival of 
2.8 years and estimated 1-year, 3-year and 5-year survival rates of 68%, 48% and 34%, respectively9. 
With the advances in PAH therapy beginning in the 1990s (initially with intravenous epoprostenol 
and later with oral therapies), data registered between 2002 and 2003 from the French registry 
showed 1-year and 3-year survival rates of 86% and 55%, respectively, in patients with incident 
idiopathic, heritable and anorexigen-induced PAH12. These patients were a homogeneous 
population, and had similar characteristics to those of patients with primary PH reported in the NIH 
registry. To date, the US-REVEAL registry is the largest PAH registry reporting survival data. A total 
of 2,635 patients with all subtypes of PAH registered between 2006 and 2009 were involved in the 
primary survival analysis, with 1-year, 3-year, 5-year and 7-year survival rates from time of 
diagnostic right-sided heart catheterization of 85%, 68%, 57% and 49%, respectively13. Data from 
the European COMPERA registry showed estimated 1-year, 2-year and 3-year survival rates of 92%, 
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83% and 74%, respectively, for patients with iPAH diagnosed between 2007 and 201114. Finally, 
data from the French registry showed that in patients with PAH diagnosed between 2007 and 2013, 
and who were treated with a strategy of upfront dual combination therapy (endothelin receptor 
antagonist and phosphodiesterase type-5 inhibitor), had 1-year, 2-year, and 3-year survival rates of 
97%, 94%, and 83%, respectively15.  
1.3. Classification 
The clinical classification of PH categorize several clinical conditions into five groups according to 
their similar clinical presentation, pathological findings, hemodynamic characteristics and 
treatment strategy16. The clinical classification may be updated when new data are available on the 
above features or when additional clinical entities are considered. A comprehensive version of the 
clinical classification is presented in Table 116. This new version of clinical classification presents 
some alterations. The first one is that new conditions, frequently found in children, have been 
included in different clinical groups, providing a comprehensive classification appropriate to both 
adult and pediatric patients. Also, recently identified gene mutations have been included in the 
HPAH subgroup of clinical group 1. The new mutations are rarer than the mutations in bone 
morphogenetic protein receptor 2 (BMPR2) gene. In addition, pre-capillary PH associated with 
chronic hemolytic anemia appears to be significantly different from other forms of PAH regarding 
pathological findings (absence of plexiform lesions), hemodynamic characteristics (PVR and high 
cardiac output (CO)) and response to PAH-specific therapies (no demonstration of efficacy). 
Consequently, these clinical conditions have been moved from group 1 (PAH) to group 5 (unclear 
and/or multifactorial mechanisms). Finally, the group 1’ [pulmonary veno-occlusive disease and/or 
pulmonary capillary hemangiomatosis] has been expanded and includes idiopathic, heritable, drug-
, toxin- and radiation-induced and associated forms17. 
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Table 1 - Classification of Pulmonary Arterial Hypertension 
 
1.4. Pathophysiology 
1.4.1. Histopathology 
PAH is an arteriopathy of small- to medium-sized pulmonary arteries which undergo remodeling 
and reduction in luminal cross-sectional area. All these pulmonary arteries layers are affected, 
occurring medial hypertrophy, intimal and adventitial thickening18,19. Medial hypertrophy is 
characterized by a proliferation of PASMCs within medial tunica, that corresponds to a hyperplasia 
(i.e., increase in number) and hypertrophy (i.e., increase in volume) of these cells. The diameter, 
from the intern to extern elastic lamina, is the measure used to define medial hypertrophy, which 
must exceed 10% cross-section diameter of the normal arteries. Typically, local hypertrophy is 
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considered reversible and an early event of PAH. Intima and adventitial thickening is a consequence 
of fibroblast, myofibroblast and other conjunctive tissue cells proliferation and/or recruitment and 
collagen deposition, causing fibrosis. The intima thickness can be classified in uniform and 
concentric or focal and eccentric. Eccentric and focal intima thickening is associated to thrombotic 
events (also known as, in situ thrombosis)18,20. 
Besides, PAH patients can exhibit various and complex lesions in the pulmonary arteries, such as 
plexiform lesions, dilated lesions and arteritis. Plexiform lesions are frequently observed in PAH 
patients. These lesions are defined by an intimal increase of small pulmonary arteries accompanied 
with endothelial cells (ECs) proliferation, leading to the formation of capillary-like channels within 
the arterial lumen. Plexiform lesions are responsible for the decrease of lumen space because of 
arterial wall extension and obliteration. Dilated lesions appear to be associated with plexiform 
lesions, and are observed as a consequence of pulmonary arterial wall thickness. Arteritis is the less 
frequent event of the complex lesions. This lesion is an inflammatory infiltrate of lymphocytes T, 
macrophages and scattered mast cells and an accumulation of necrotic and fibrotic tissue in the 
arteries wall20,21. 
These phenomena are responsible for the pulmonary arteries obstruction that leads to the increase 
of their resistance and decreasing of the blood flow, leading to RV overload and hypertrophy and, 
consequently to HF and ultimately to death22. 
1.4.2. Cellular changes 
The main mechanisms responsible for pulmonary vascular dysfunction are the abnormal 
proliferation of pulmonary arterial smooth muscle cells (PASMCs) and pulmonary arterial 
endothelial cells (PAECs), infiltration of inflammatory cells and fibrosis23. 
PAH is not only associated with cell proliferation, but also with apoptotic processes, as the 
imbalance between these two events is the major cause of the narrowing of the pulmonary arteries 
in PAH24. 
Smooth muscles cells and fibroblasts 
A typical characteristic of PAH remodeling is the distal extension of smooth muscle into small 
peripheral, usually nonmuscular, pulmonary arteries within the respiratory acinus. The cellular 
processes underlying muscularization of this distal part of the pulmonary arterial tree are 
incompletely understood. This uncontrolled proliferation of PASMCs eventually leads to 
hypertrophy of the media and contributes to the thickening of the intima and adventitia of the 
arterial wall. These modifications in the vascular wall lead to the decrease of the vessel lumen, 
consequently contributing to increased arterial pressure25. 
Another feature observed in muscularized arteries affected by PAH is the development of an 
extracellular matrix and myofibroblast layer between the endothelium and internal elastic lamina, 
named neointima25. In some model systems, mostly in hypoxia models, the first activated cell to 
proliferate and to synthesize matrix proteins in response to the pulmonary hypertensive stimulus 
appears to be the adventitial fibroblast. The mechanisms that allow the adventitial fibroblast to 
migrate into the media, and ultimately into the intima, are unclear. It has been suggested that 
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upregulation of matrix metalloproteinases (MMP2 and MMP9), which are involved in cell migration, 
plays a role in fibroblast migration. These proteins are enzymes with proteolytic activity, that 
degrade extracellular matrix proteins during invasive events. The MMP2 and MMP9 can also 
degrade type IV collagen in the basal lamina, which is probably responsible for the invasive 
process26. 
In the different forms of PAH, as the vessel wall thickens, a concurrent increase occurs in 
neovascularization of the vasa vasorum. This progression affects primarily the adventitia but can 
extend up to the media27. 
Endothelial cells 
The endothelium plays an important role in the regulation of pulmonary blood flow and vascular 
resistance. In many cases of PAH, it is described that disorganized proliferation of ECs results in 
plexiform lesions development, but it is unknown the cause of this phenomena28. Hypoxia, shear 
stress, inflammation, viral infections or response to drugs or toxins on a background of genetic 
susceptibility is suggested to be the initial stimulus for this abnormal proliferation of endothelial 
cells3. 
In response to stimulation, endothelial cells undergo changes not only at the proliferative and 
apoptotic levels, but also at the functional level. The impaired functional capacity of ECs can result 
in an imbalance between the synthesis of vasoconstrictors/vasodilators, activating/inhibitory 
growth and migration of PASMCs, prothrombotic/antithrombotic mediators and pro-
inflammatory/anti-inflammatory signals29. 
Inflammatory cells 
Inflammatory mechanisms appear to play an important role in PAH. Infiltration of various 
inflammatory cells and the increased expression of some cytokines chemokines (interleukin IL-1β, 
IL-6, IL-8, monocyte chemoattractant protein-1, fractalkine, CCL5/RANTES and tumor necrosis 
factor) occurs in remodeled pulmonary vessel, leading to an inflammatory mechanism 
deregulation30. Various types of PAH, including iPAH and PAH associated with connective tissue 
diseases or with infectious etiologies such as HIV, are characterized by accumulation of 
macrophages, T and B lymphocytes and dendritic cells in vascular lesions31. 
Additionally, other alterations can directly contribute to the recruitment of inflammatory cells to 
the pulmonary vascular remodeling process, which includes increased expression of growth factors 
(e.g., endothelial growth factor and platelet-derived growth factor), transcriptional factors (e.g., 
nuclear factor of activated T cells), and viral protein components (e.g., HIV-1 negative regulatory 
factor)32. 
Platelets and thrombosis 
Patients with PAH often present thrombotic lesions and platelet dysfunction. In pulmonary 
vasculature, the decrease of blood flow leads to an increased risk of thrombosis in situ33. In the 
response to injury or endothelial dysfunction, activation of circulating platelets occurs22. Activated 
platelets can release vital vasoconstrictors, such as thromboxane A2, platelet activating factors, 
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serotonin, as well as important growth factors, such as epidermal growth factor (EGF) and vascular 
endothelial growth factor (VEGF). These factors will promote the worsening of vascular remodeling. 
Another important biological evidence of continuous intravascular coagulation processes and 
changed fibrinolytic activity of vascular endothelium of patients with PAH is the increase of levels 
of D-dimer, fibrin (fibrinopeptide A), von Willebrand factor, and plasminogen activator inhibitor 
(type I) in the plasma of these patients34. 
1.4.3. Molecular abnormalities and therapeutic targets 
Pulmonary vasoconstriction is supposed to be an early event of the pulmonary hypertensive 
process. Excessive vasoconstriction has been connected to abnormal function or expression of 
potassium channels, as well as to endothelial dysfunction. Endothelial dysfunction leads to 
recurrent impaired production of vasodilators (nitric oxide and prostacyclin), along with prolonged 
overexpression of vasoconstrictors (endothelin). These signaling molecules not only affect vascular 
tone, but also promote vascular remodeling, and, therefore, are key therapeutic targets for the 
management of PAH25 (Fig. 1). 
 
Figure 1 - Current therapies for PAH. Currently approved therapeutic options (green boxes) and new therapies under 
development (grey boxes). Black arrows represent stimulation, while red arrows represent inhibition of targeted 
pathways. Abbreviations: AC, adenylate cyclase; cAMP, cyclic AMP; cGMP, cyclic GMP; ECE-1, endothelin converting 
enzyme 1; eNOS, endothelial nitric oxide synthase; ETA endothelin receptor type A; ETB, endothelin receptor type B; ERA, 
endothelin receptor antagonists; IP, prostaglandin I2; PDE-5, phosphodiesterase type 5; PDGF, platelet derived growth 
factor; PDGF-R TKI, PDGF receptor tyrosine kinase inhibitors; PGIS, prostaglandin I synthase; sGC, soluble guanylate 
cyclase. Adapted from O’Callaghan  et al.35. 
Prostanoids 
Prostacyclin (or prostaglandin I2) and thromboxane A2 belong to the prostanoid family, and are 
produced from arachidonic acid metabolites. Prostacyclin is a potent vasodilator and inhibitor of 
platelet activation, while thromboxane A2 has opposite effects36. The vascular ECs produce 
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prostacyclin, which acts on both systemic and pulmonary vascular smooth muscle cells, as well as 
on circulating platelets and other cells, via the cyclic adenosine monophosphate (cAMP) pathway37. 
Prostacyclin plays a significant role in antiproliferative, antithrombotic, antimitogenic and 
immunomodulatory activity37. In PAH patients, the expression of prostacyclin synthase in the 
pulmonary arteries is reduced, and therefore the production of prostacyclin in ECs is decreased. In 
fact, patients with PAH have reduced endogenous prostacyclin38. 
Therefore, prostacyclin analogues are an established PAH therapy, which mimic the prostacyclin 
signaling pathway and are able to induce vasodilation while inhibiting platelet activation37. 
Endothelin-1 
Endothelin-1 (ET-1), a 21-amino acid vasoactive peptide, is expressed in numerous mammalian 
tissues in different types of cells. ET-1 regulates the vascular tone and acts through interaction with 
two different types of receptor: ET receptor type A (ETA) and ET receptor type B (ETB). These 
receptors belong to the G-protein-coupled receptor family.  
Both receptors have a vasoconstrictor effect when activated in PASMC. However, PAECs don’t 
express ETA, and ETB activation leads to vasodilatation39. Overexpression of ET-1 is observed in 
endothelial cell dysfunction, which contributes to decrease the synthesis of NO and prostacyclin, 
and consequent worsening of the vasoconstriction response. Inflammatory responses and 
increased fibrosis are also the result of an upregulation of ET-1. In patients with PAH, ET-1 clearance 
by the pulmonary vasculature is decreased, and its plasma concentrations are raised and relate with 
PAH harshness and prognosis40,41. Nowadays, ET receptor antagonists are used as treatment for 
PAH, differing in their selectivity for ETA and ETB receptors. The therapies targeting this pathway 
can be dual, if they block both receptors, or selective if they only block ETA39,42. 
Endothelial nitric oxide 
Nitric oxide, a gaseous molecule, can be produced from L-arginine in mammalian tissues via 
activation of one of the NO synthase isoforms. NO is a vasodilator that controls several physiological 
processes, and is also able of preventing leukocyte adhesion, platelet aggregation, thrombus 
formation and vascular proliferation37. Endothelial NO synthase can be activated either by G-
protein-coupled receptor signal transduction, Akt signaling, VEGF and hormonal stimuli (e.g. 
estrogen and insulin)39.  
In both PAH animal models and humans, pulmonary vascular endothelial NO synthase activity is 
decreased, along with NO bioavailability decay. The latter is connected to impaired endothelium-
dependent and -independent vasodilatation, improved PASMCs mitogenesis and platelet 
aggregation39,43. 
Phosphodiesterases 
Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) are 
degraded by phosphodiesterases (PDE). Nowadays, eleven isoforms of PDE are known in 
mammalian tissues44. PDE-5 was found in high concentrations in PASMCs, platelets and myocytes, 
gathering interest to PAH studies. 
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PDE-5 regulates cGMP bioactivity via hydrolysis of cGMP to GMP. The allosteric binding of cGMP to 
PDE-5 induces a conformational modification to the enzyme structure, and positively feeds back to 
promote metabolism of cGMP39. In PAH, the expression of PDE-5 is increased in PASMCs and RV 
myocytes45,46, as a result of decreased levels of NO, pulmonary vascular dysfunction and impaired 
RV lusitropy47. As the vasodilatory activity of NO in PASMCs is accomplished via cGMP signaling 
pathway, PDE inhibitors are used in the treatment of PAH, since they can delay the enzymatic 
breakdown of cGMP, and thus have vasodilator effects37. 
Mitochondrial dysfunction and voltage-gated potassium channels (Kv channels) 
In PAH, likewise to cancer, smooth muscle cell mitochondria have repressed glucose oxidation and 
increased cytoplasmic glycolysis, in line with inhibition of pyruvate dehydrogenase48. The decreased 
pyruvate metabolism slows down the Krebs cycle and the electron transport chain (ETC), which is 
accompanied by reduction of reactive oxygen species (ROS) and α-ketoglutarate. The decreased 
synthesis of ROS inhibits membrane Kv channels, resulting in the increase of intracellular calcium49. 
These changes are caused by various stimuli, such hypoxia or anorexigens49, and contribute to the 
activation of the hypoxia-inducible factor-1 alpha (HIF-1α)50 and the NFAT51. HIF-1α and NFAT 
contribute to the downregulation of Kv channel expression and to the reduction of mitochondrial 
factors and enzymes, leading to the suppression of glycolysis and the remodeling process in smooth 
muscle cells that is typical in PAH. Some Kv channels are downregulated in the smooth muscle cells 
of PAH patients52, and consequently gene transfer of these types of channels has been used in 
animal models, as an experimental strategy to avoid and/or attenuate PAH53. Furthermore, the 
inhibition of pyruvate dehydrogenase through dichloroacetate administration seems to reverse 
mitochondrial irregularities and Kv channel dysfunction, leading to reversion of pulmonary vascular 
remodeling48,54. 
Serotonin and Rho proteins 
Serotonin (5-hydroxytryptamine, 5-HT) is a vasoconstrictor that can induce hypertrophy and 
hyperplasia in PASMC36. The 5-HT transporter (5-HTT) enables the induction of proliferation by 
carrying 5-HT into PASMCs, while the 5-HT1B receptor mediates vasoconstriction. Both processes 
contribute to PAH pathogenesis55. Patients with PAH usually present increased plasmatic 
concentrations of 5-HT56.  
Rho proteins, especially Rho protein A, regulate cellular functions, such as contraction, migration, 
proliferation and apoptosis. Rho kinases have been implicated in PAH vasoconstriction and vascular 
remodeling57. During the PAH progression, 5-HTT-mediated PASMC proliferation and platelet 
activation involve the signaling pathway of these proteins58. 5-HT-induced proliferation re relies on 
the activation of Rho kinase by 5-HT1B/D receptors, triggering nuclear translocation of extracellular 
signal-regulated kinases (ERK) and the activation of GATA4-dependent transcriptional pathway that 
is involved in cell proliferation59.  
Genetic mutations 
If not associated with other clinical condition or induced by toxins, PAH can be either idiopathic or 
heritable. This disease segregates an autosomal dominant trait with a markedly reduced 
penetrance, since only 10-20% of individuals that carry the mutation will develop PAH60. The bone 
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morphogenetic protein receptor type 2 (BMPR2) gene encodes for a serine/threonine receptor 
kinase that belongs to the family of transforming growth factor beta (TGF-β). It is considered the 
major responsible for the development of 75% of heritable PAH and approximately 25% of iPAH61,62. 
Mutations in BMPR2 cause an aberrant signal transduction in PASMC, resulting in an imbalance 
between apoptosis and proliferation in favor of the latter63. The pathway downstream of BMPR2 
activation is tightly regulated by the small mothers against decapentaplegic (SMAD) cascade, which 
begins with the phosphorylation of SMAD1, 5 and/or 8 that bind to SMAD 4 and enter the nucleus 
to drive transcription64. SMAD proteins also can regulate microRNA splicing through a non-
transcriptional mechanism65. Thus, this signaling pathway regulates smooth muscle differentiation 
state by either direct transcriptional regulation of genes involved in the maintenance of a 
differentiated and contractile state or by regulation of miRNAs66. 
Other two PAH predisposing genes are activin-like kinase type I (ALK1) that codes for ALK1 receptor, 
present in ECs, and endoglin, and are most common in patients displaying hereditary hemorrhagic 
telangiectasia67,68.  
Interestingly, all genes mentioned above encode proteins involved in the TGF-β signaling pathway, 
that controls growth, differentiation and apoptosis in different cell types and may be a trigger for 
pulmonary vascular remodeling69. 
Recently, Ma et al.70 identified the potassium channel subfamily K member 3 (KCNK3) as a novel 
gene in PAH pathogenesis. KCNK3 codes for a distinct family of mammalian potassium channels, 
non-voltage-dependent, that seems to have a crucial role in the regulation of resting membrane 
potential and pulmonary vascular tone. In PAH, KCNK3 is important in the vascular remodeling 
process, since it prevents or attenuates apoptosis. Moreover, the presence of loss-of-function 
mutations can lead to vasoconstriction, through the depolarization of the resting membrane 
potential. 
1.4.4. Right ventricle 
The integrity of RV function, rather than the degree of vascular injury, is the major determinant of 
prognosis in PAH71. The abnormal changes that occur in the pulmonary arteries of PAH patients, at 
first lead to vessel narrowing and/or obstruction, which then results in a progressive increase in 
PVR and mPAP72. 
In a healthy heart, the RV, which differs anatomically from the left ventricle (LV), can adapt and 
respond to an increase in load with an increase in contractility since its thin wall, crescent shape 
and greater compliance give the RV the ability to adapt rapidly to changes in volume and pressure 
load71. 
In PAH patients, the RV copes with increased afterload and with an enhanced contraction and a 
concentric RV remodeling, while the right atrium pressure remains normal. The rise in ventricular 
pressures increases diastolic and systolic stretch on the RV wall, which firstly leads to an increase 
in muscle mass – adaptive hypertrophy – due to increased protein synthesis and cardiomyocyte 
size. However, if the pressure overload is maintained, the RV cannot sustain the adaptive 
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hypertrophy and eventually dilates, without any increase in RV contractility, despite further 
increases in load, reaching a state called uncoupling of the RV73. 
The mechanisms involved in further adaptation of the RV and decline of its contractility are poorly 
understood. Apparently, it is associated with an imbalance between oxygen supply and demand74, 
increased chronic sympathetic activation75, oxidative and nitrosative stress, immune activation and 
cardiomyocyte apoptosis73. 
The increase in ventricular volume may also lead to tricuspid regurgitation, resulting in further RV 
volume overload and functional decline. The latter is accompanied by an increase in RV contraction 
time and ventricular asynchrony, together with a reduction in RV stroke volume, leading to 
underfilling of the left ventricle76. Impaired left ventricular filling in concert with RV dysfunction 
contributes to the evident decline in CO seen in severe cases of PAH and, if not interrupted, this 
circle of events ends in right HF and death72.  
1.5. Experimental animal models in PAH.  
To better understand the pathophysiological mechanism and remodeling process behind PAH, and 
discovery of novel therapeutic agents, a variety of animal models have been developed and 
characterized. These experimental in vivo models mimic certain histological and molecular 
characteristics seen in PAH pathophysiology in humans. These include endothelial dysfunction, 
muscularization of previously non-muscular arterioles and increased medial thickness of normally 
muscularized arterioles, in situ thrombosis and plexiform lesions appearance77. Currently, there are 
several techniques available to induce PAH-associated alterations in animals, such as chemical 
agents78,79, genetic manipulation80,81, environmental factors82 and surgical procedures83 (Table 2). 
Currently, monocrotaline (MCT) administration and chronic exposure to hypoxia are the most 
widely used models of PH in translational research, due to good reproducibility and well described 
histopathology.  
Although no animal model completely presents all the features of human disease, they may 
correlate with milder forms of human PH, a phase that is frequently missed at the time of 
diagnosis84. Nevertheless, animal models have experienced major developments and 
improvements over the years, and multiple-pathological-insult models appear to correlate better 
with PH in humans. All the models have contributed to a better understanding of PAH and 
development of novel therapies84,85. 
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Table 2 - Experimental animal models of pulmonary arterial hypertension 
Animal model Species Histological Features Advantages Disadvantages 
MCT 
Sheep; 
dog; rat 
Medial hypertrophy; 
muscularization of non-
muscular arteries; vascular 
inflammation 
Severe PH; RV failure; 
predictable and 
reproducible 
Toxic stimulus; no 
plexiform lesions 
MCT + 
pneumectomy 
Rat 
Medial hypertrophy; 
muscularization of non-
muscular arteries; 
neointima formation 
Severe PH; RV failure; 
proliferation of 
endothelial cells 
Toxic stimulus; difficult 
manipulation 
BMPR2 knockout Mouse 
 
↑ Muscularization 
Well-suited to study the 
genetic factors that 
contribute to PH 
Homozygous knockouts 
die in utero 
Fawn-hooded rat 
 
Rat ↑ Muscularization 
Well-suited to study the 
genetic factors that 
contribute to PH; 
Presence of plexiform 
lesions 
Presence of systemic 
hypertension 
Overexpression 
of S100A4 
Mouse Plexiform lesions 
Presence of plexiform 
lesions 
Only 5% of S100A4 
overexpressing mice 
develop PH 
Chronic hypoxia 
+ SU5416 
Rat 
Medial hypertrophy; 
muscularization of non-
muscular arteries; 
neointima formation; 
plexiform lesions 
Physiological stimulus; 
proliferation of 
endothelial 
Not clear which group 
it mimics 
Schistosomiasis Mouse 
Perivascular inflammation; 
medial thickening; 
formation of plexiform-like 
lesions 
Comparable to human 
schistosomiasis 
associated with PAH 
Not significant PH 
Left-to-right 
shunt 
Sheep; pig; 
dog; rat 
Medial hypertrophy; ↑ 
VSMC proliferation; 
intimal proliferation; 
plexiform lesions can be 
seen 
Imitate the formation of 
plexiform lesions in 
human severe PAH 
Sophisticated surgical 
approaches; 
pathological alterations 
can appear at a late 
stage 
Closure of the 
ductus arteriosus 
Fetal and 
newborn 
lambs 
Medial hypertrophy; 
muscularization of non-
muscular arteries; 
adventitial fibrosis 
Relatively large size of 
the fetal lamb; uterine 
surgical intervention is 
well tolerated 
Sophisticated surgical 
approaches; 
pathological alterations 
can appear at a late 
stage 
BMPR2: bone morphogenetic protein receptor type 2 gene; PAH: pulmonary arterial hypertension; PH: pulmonary 
hypertension; RV: right ventricle; S100A4: S100 calcium-binding protein A4 gene; SU5416: vascular endothelial growth 
factor receptor inhibitor; VSMC: vascular smooth muscle cells. Adapted from Santos-Ribeiro et al.21.  
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2. Metabolic abnormalities in PAH 
As previous mentioned, PAH is a highly morbid and fatal disease and it’s considered an arteriopathy 
of small-to-medium-sized pulmonary arteries16,18,86,87. However, PAH is progressively being 
recognized as a systemic disease with a preference for the pulmonary vasculature and RV88.  
Besides that, iPAH has been associated to various systemic metabolic imbalances. Previous studies 
emphasized the role of insulin resistance, glucose intolerance, and the metabolic syndrome in 
PAH89-92. The main alterations are in aerobic glycolysis, fatty acid oxidation (FAO), and the 
tricarboxylic acid (TCA) cycle93. These metabolic changes lead to the progression of PAH and 
development of lipotoxicity in the RV94 (Fig. 2). 
 
 
2.1. Metabolic changes in the pulmonary vasculature 
In 1924, Otto Warburg discovered that tumor cells convert glucose to lactate even in sufficiently 
oxygen, sustaining the mitochondrial oxidative phosphorylation. Since then, this metabolic 
abnormality is called Warburg effect95. Various studies discovered that PAH and cancer have 
multiple similarities, namely dysregulated angiogenesis, development of antiapoptotic activity and, 
primarily, the Warburg effect96,97. Recently, the Warburg effect was purposed to be responsible for 
mitochondrial changes in PAH, in which mitochondria play an important role in adenosine 
triphosphate (ATP) production through oxidative phosphorylation98. In addition, the Warburg effect 
plays a significant role in PAH, due to the contribution in the abnormal proliferation of PASMCs and 
endothelial dysfunction99. However, it isn’t known if this effect is involved in the genesis or progress 
of PAH.  
Figure 2 - Metabolism in PAH. Metabolism in PAH is perturbed like what is observed in cancer. Glycolysis occurs when 
glucose is taken up by the glucose transporters 1 (GLUT1) and 4 (GLUT4), gets phosphorylated by hexokinase (HK), and 
goes through a series of reactions to produce pyruvate. Pyruvate is the substrate for pyruvate dehydrogenase (PDH) in 
the mitochondria to support glucose oxidation. Free fatty acids (FFA) are taken up by fatty acid transport protein-1 (FATP-
1) and -6 (FATP-6) and transformed to acyl carnitines that are shuttled across the mitochondrial membrane by carnitine 
palmitoyltransferase-1 (CPT1) and transformed to acyl CoA by carnitine palmitoyltransferase-2 (CPT2). Acyl CoA is 
converted to acetyl CoA during β-oxidation. In PAH, aerobic glycolysis is intensified, due to normoxic upregulation of HIF-
1α, which upregulates pyruvate dehydrogenase kinase (PDK) to inhibit pyruvate dehydrogenase, and epigenetic 
regulation of the superoxide dismutase 2 (SOD2) gene. PFK, phosphofructokinase; PK, pyruvate kinase; LDH, lactate 
dehydrogenase; ROS, reactive oxygen species; ETC, electron transport chain. Adapted from: Molecular Mechanisms of 
Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. 
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2.1.1. Warburg effect in PASMCs 
In PAH occurs up-regulation of growth factors100, as well as a metabolic shift101, which involves the 
recruitment of inflammatory and immune cells, increasing the expression of cytokine and 
chemokines102. This increase causes mitochondrial membrane hyperpolarization and subsequent 
hyperproliferation of PASMCs and apoptosis resistance. Some studies haves shown that both 
SIRT3/STAT3/NFAc2/Kv and PDGF/HIF-1α signaling pathways are involved in the Warburg effect in 
PASMCs hyperproliferation103.  
Via SIRT3/STAT3/NFATc2/Kv signaling pathway 
Sirtuin3 (SIRT3) is the most mitochondrial sirtuin characterized so far104. SIRT3 belongs to NAD+-
dependent histone deacetylase family105, which regulates the mitochondrial function through 
deacetylation activity that activates multiple ETC complexes and enzymes. SIRT3 compromises 
oxidative phosphorylation and stimulates glucose uptake and glycolysis (Warburg effect)104. SIRT3 
is also an important regulator of metabolic homeostasis in PASMCs, since a lack of SIRT3 promotes 
the development of PAH through the increase of acetylation of ETC complexes and enzymes, 
suppressing the mitochondrial oxidative phosphorylation106 and inhibiting mitochondria-
dependent apoptosis104. Downstream mitochondrial signaling it promotes the activation of 
proliferative and antiapoptotic transcription factors that are vital in human and animal PAH, 
including the signal transducer and activator of transcription 3 (STAT3)107 and the NFAT108. STAT3 is 
one of the seven STAT family isoforms and the most important in cardiovascular disease109. 
Mitochondrial STAT3 increases the activity of complexes I and II of the respiratory chain in a 
transcription-independent manner110,111. The STAT3 target gene is the provirus integration site for 
Moloney murine leukemia (PIM1). Curiously, PIM1 activation enhances the NFAT isoform 2 
(NFATc2) 109. NFATc2 is a master activator of T cells and stimulates the transcription of several 
inflammatory mediators in T and B cells112. NFATc2 plays a crucial role in promoting proliferation 
and apoptosis inhibition in PASMCs of PAH, due to its role in glycolysis and regulation of glycolytic 
enzymes transcription104. Besides, the NFATc2 target gene KCNA5 encodes the voltage-gated 
potassium channel (Kv1.5), and KCNA5 mRNA levels are reduced in SIRT3-KO PASMCs104. As Kv1.5 
regulates the resting plasma membrane potential in PASMC, its loss or inhibition causes plasma 
membrane depolarization and Ca2+ influx, which lead to an increase in Ca2+ that further enhances 
NFATc2 activation within a positive feedback loop, contributing to its sustained activation113. 
Via PDGF/HIF-1α signaling pathway 
Platelet-derived growth factor (PDGF) acts as a chemokine via activation of two PDGF receptor 
(PDGFR) subunits, PDGFRα and PDGFRβ, which promotes several cellular responses, such as 
proliferation, migration, cellular survival and transformation, in various types of cells114,115. PDGF 
binds to its receptor, leading to the dimerization of two receptor subunits and, consequently, 
increases the activity of receptor’s tyrosine kinase, which results in a receptor trans- or auto-
phosphorylation. The complex formed by PDGF and PDGFRs leads to activation of receptor-
associated signaling molecules and triggers downstream signal cascades, facilitating PDGF-
dependent cellular responses, such as protein synthesis, proliferation, migration, apoptosis 
resistance and cellular transformation114-116. 
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The lungs of both MCT- and hypoxia-induced experimental PAH animals and PAH patients revealed 
that PDGF and its receptor are up-regulated116,117. This feature was also observed in PASMCs117,118. 
Persistent activation of PDGF causes pulmonary vascular remodeling and PAH in mice with chronic 
hypoxia-induced PAH119. PDGFRβ signaling enhancement and PDGF-dependent proliferation 
caused by chronic hypoxia-induced by PDGF signaling have been observed in human PASMCs 120. 
Frequently, hypoxia is present within lungs of PAH patients and it’s a modulator of RTK signaling, 
activating hypoxia-inducible factor 1 (HIF-1). This transcriptional factor is an important modulator 
of hypoxia transcriptional responses, having a crucial role in the progression of PAH121,122. HIF-1 is 
a heterodimeric protein with two subunits, HIF-1α and HIF-1β122,123. The subunit HIF-1α is a prolyl 
hydroxylase that bind to von Hippel-Lindau tumor suppressor protein (VHL), under normoxia 
conditions. The complex HIF-1α/VHL promotes the HIF’s ubiquitination and degradation120,122. It is 
known that HIF-1α controls the proliferation of PASMCs via two signaling pathways, such as PDGF 
signaling or via Warburg Effect120.  In the first pathway, the PASMC hyperproliferation verified, 
occurs as consequence of hypoxia, which increase the PDGF signaling in PA by HIF-1α- dependent 
down-regulation of protein tyrosine phosphatases (PTPs) expression and activity. PTP, a PDGF 
antagonist, promote the constant activation and phosphorylation of PDGF, leading to proliferation 
of PASMC120. The other pathway implicates the Warburg Effect and activation of glycolytic genes 
through HIF-1α, increasing the conversion of glucose to pyruvate and consequently in lactate as an 
important hypoxia adaptor. HIF-1α also suppress actively the metabolism of TCA cycle, directly 
activating the gene encoding pyruvate dehydrogenase kinase 1 (PDK1). PDK1 inhibits pyruvate 
dehydrogenase (PDH), an enzyme of TCA cycle, leading to the interruption of mitochondrial 
oxidative phosphorylation. This increase of PDK1 expression leads to an enhancement of ATP levels 
and decreases ROS synthesis by attenuating cells oxidative metabolism. These decrease leads to an 
inhibition of Kv channels, promoting potassium accumulation124,125. High concentrations of 
intracellular potassium inhibit caspases and apoptosis, along with cellular depolarization. 
Membrane depolarization enhances L-type calcium channels, permitting calcium influx. The 
increased calcium levels trigger calcineurin, which dephosphorylates NFATs. Dephosphorylated 
NFATs are active and works as transcriptional factors inhibiting Kv channels and increasing 
mitochondrial B-cell lymphoma 2 (BCL-2) levels. BCL-2 causes hydrogen ions efflux from the 
mitochondria, resulting in its hyperpolarization, impeding pro-apoptotic molecules release and 
promoting cell hyperpolarization98.  
2.1.2. Warburg effect in endothelial dysfunction 
The pulmonary vascular remodeling verified in PAH is mainly caused by excessive proliferation of 
ECs and PAEC dysfunction126. Recently, it has been confirmed that the Warburg effect is present in 
PAH, and studies in PAH patients and laboratory PAH animal models confirm that PAECs also switch 
glucose metabolism from glycolytic metabolism to aerobic glycolysis in PAH127, and the metabolic 
shifts are analogous to cancer cell metabolism128. However, whether or how the Warburg effect 
mediates PAEC dysfunction in PAH is unknown. It has been shown that PAEC dysfunction involves 
HIF-1α, BMPR2 and caveolin-1 mediated via the Warburg effect.  
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BMPR2 
BMPR2 is a member of the TGF-β superfamily of transmembrane serine/threonine kinase 
receptors. Signal transduction through the BMP pathway involves heterodimerization of BMPR2 
with BMPR1, resulting in BMPR1 phosphorylation and activating signal transduction129. Newly, 
mutations in BMPR2 have been documented in patients with iPAH. BMPR2 signaling promotes 
survival in PAECs, and the lack of BMPR2 signaling  improves PAECs apoptosis in PAH127. Some 
animal models of PAH show a shift towards aerobic glycolysis, modifications in glucose uptake and 
utilization, and changes in mitochondrial oxidative phosphorylation. The same observations were 
also seen and confirmed in the PAECs from patients with PAH130. Furthermore, during hypoxia-
reoxygenation in PAH, reduced BMPR2 decreases mitochondrial biogenesis and ATP production and 
promotes mitochondrial deoxyribonucleic acid injury and PAEC apoptosis131. Interestingly, this 
feature has been observed in PAECs from PAH patients with BMPR2 mutations. BMPR2 gene 
mutations leads to an increase activity of isocitrate dehydrogenase, an enzyme of TCA cycle, in 
pulmonary microvascular ECs and serum samples of patients with PAH. These results indicate that 
BMPR2 mutations promote pulmonary microvascular ECs dysfunction via reprogramming cell 
metabolism in PAH93.  
Caveolin-1 
Caveolin-1 gene belongs to the caveolin gene family and is extremely expressed in adipocytes, 
epithelial cells, fibroblasts and myocytes132. Caveolin-1 is a protein that interacts and negatively 
regulates other proteins, such as G-proteins and G-protein-coupled receptors, endothelial nitric 
oxide synthases (eNOS) and several growth factor receptors132, Actually, caveolin-1 is an anchor 
within caveolae holding numerous proteins to regulate their function through its scaffolding 
domain133. Caveolin-1 deficiency plays a serious role in the pathogenesis of PAH. The lungs of 
caveolin-1 deficient mice exhibit PH and the hearts show right ventricle hypertrophy (RVH). 
Hemodynamic measurements also exhibit a significant increase in right ventricular contractility and 
diastolic function in the lungs of caveolin-1 knockdown mice134. Furthermore, lack of endothelial 
caveolin-1 has been described in clinical PAH patients and experimental PAH mouse models, 
resulting in ECs damage and dysfunction. Curiously, one study has reported that caveolin-1 inhibits 
eNOS by its interaction, and eNOS is predominantly expressed in endothelial cells135. The loss of 
caveolin-1 results in persistent eNOS activation and increased ROS production, further impairing 
PAECS in PAH134. 
Moreover, lack of caveolin-1 causes mitochondrial dysfunction, membrane hyperpolarization, and 
mitochondrial synthesize of oxidant species, which is considered the underlying cause of the 
metabolic switch or the Warburg effect in PAECs. The precise signaling pathway responsible for the 
loss of caveolin-1, which mediates PAEC dysfunction through the Warburg effect, has not been 
established. Though, absence of caveolin-1 in PAH activates eNOS, increases ROS, impairs 
mitochondrial function with a metabolic shift towards the Warburg effect, and ultimately results in 
PAEC hyperproliferative or dysfunction136. 
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HIF-1α 
HIF-1α is an oxygen-sensitive alpha subunit of HIFs, which regulate genes that control energy 
metabolism, vasomotor tone and angiogenesis121. Moreover, HIF-1α plays a pathologic role in 
PAH122 and is directly involved in the metabolic shift of PAECs towards the Warburg effect127. 
Unusually, it has been demonstrated that HIF-1α expression and the downstream target gene VEGF 
play an important role in endothelial plexiform lesions, which suggests that HIF-dependent signaling  
contributes to the hyperproliferative of PAECs and metabolic abnormalities in PAH137. 
Curiously, irregularities of NO that are verified in PAECs with PAH may further contribute to the 
activation of HIF-1α in PAH and activate various intracellular signaling  pathways127. Under hypoxia, 
HIF-1α is destabilized by low levels of NO, and the low concentrations of NO inhibit mitochondrial 
oxidative metabolism, which contributes to a cellular metabolic shift towards the Warburg effect138. 
In addition, cellular metabolism is inhibited by NO under hypoxia, which increases intracellular O2 
availability and promotes degradation of HIF-1α. It is appealing to hypothesize that the lack of NO 
synthesis may promote HIF activation in PAH endothelial cells, which are likely all involved in the 
development of PAEC dysfunction via the Warburg effect50,139. 
2.2. Metabolic changes in the RV 
While pathological changes in the pulmonary vasculature have been the outdated subject of most 
intensive study in PAH, structural remodeling of the RV means a much worse prognosis, thus 
suggesting its distinct importance to this disease140. As the disease syndrome progresses, the RV is 
forced to maintain CO in the face of mounting vascular resistance. This leads to RVH that, in turn, 
carries a greater oxygen requirement that cannot be met by coronary blood flow140. In cases of 
adaptive remodeling, RVH does not lead to RV failure; but in many PH patients, termed maladaptive 
remodelers, RVH is closely followed by a loss of RV function140. Current understanding of the 
mechanisms involved in RVH remains limited and, perhaps erroneously, relies heavily on data 
extrapolated from studies of the LV. Evidence of a Warburg phenotype specifically in the RV, 
however, has emerged and is consistent with prior knowledge of suppressed oxidative 
phosphorylation during LV overload141. Thus, these molecular events represent the first available 
clues that may help to elucidate the potential importance of metabolic dysfunction in the RV as it 
controls the clinical course of PH. In contrast with the pulmonary vasculature, 60–90% of ATP 
produced in the myocardium is derived from FAO. The other 10–40% is accounted for by glucose 
oxidation140. FAO and glucose oxidation share a mutually inhibitory relationship in tissue, as defined 
by the Randle cycle. This relationship is common to most muscle and adipose tissues and occurs 
without any form of hormonal mediation142. Confronted with an increased oxygen requirement and 
a decreased oxygen supply, it is thought that hypertrophic RV tissue experiences higher degrees of 
hypoxia, resulting in the activation of transcription factors HIF-1 and Myc143,144. As in the pulmonary 
vasculature, the activation of HIF-1 produces a glycolytic phenotype via up-regulation of glycolytic 
enzymes and suppression of glucose oxidation. This has been demonstrated by evidence of a 
glycolytic shift in several experimental models of RV dysfunction. For example, using positron 
emission tomography (PET), Oikawa et al.145 reported that glucose uptake is unusually high in the 
RV in both human RVH patients and in animal disease models. It has also been demonstrated that 
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the glucose transporters 1 (GLUT1) and 4 (GLUT4), as well as the rate-limiting glycolytic enzyme HK-
II, are all up-regulated in a variety of RVH models140,146. 
Moreover, Piao et al.140 confirmed that rats experiencing MCT-induced RVH display increased 
activation of PDK1. FAO has also been shown to be impaired in severe cases of hypoxic PH and PAH, 
although this effect was not seen in milder forms of either disease. Importantly, FAO requires more 
oxygen per unit of ATP than glucose oxidation by about 12%140. It is likely that myocardial FAO is 
unable to compensate for the ATP production lost when glucose oxidation is suppressed, even in 
cases where FAO itself is relatively spared. Because anaerobic glycolysis is inherently less efficient 
for ATP generation than oxidative phosphorylation, it has been proposed that insufficient energy 
production induces RV hibernation as seen in late-stage RVH140. This idea is supported by studies 
that contrast adaptive and maladaptive RV remodeling, such as those demonstrating that p38-
MAPK, a promoter of glycolysis, is increasingly activated by maladaptive, but not the adaptive, RV 
alterations147. 
3. Neuregulin-1 
3.1. Neuregulin and their receptor 
Neuregulins (NRGs) are a subclass of transmembrane polypeptide growth factors belonging to the 
EGF family. Normally, these proteins are expressed in the nervous system, the cardiovascular 
system, mammary glands, the intestine and kidneys148. It exists four different genes, NRG1 to NRG4, 
which codes for distinct NRG proteins. Every gene contains various promotors and, along with 
alternative splicing sites, it results in more NRG protein variants. In this thesis, NRG1 will be the 
focus due to its recognized effects in the cardiovascular system.  
NRG1 release occurs at the plasma membrane when the N-terminal ectodomain of pro-NRG1 
undergoes proteolytic cleavage by specific proteases, namely b-secretase 1, and a disintegrin and 
metalloproteinase domain containing protein. In addition, NRG1 mRNA can be alternatively spliced, 
resulting in many different isoforms149. The final biological activity of these protein isoforms is 
defined by functional differences and actions through paracrine or juxtacrine communication 
pathways150. The NRG1 mRNA expression and protein synthesis are mediated by neurohormones 
(e.g., angiotensin II and phenylephrine inhibit and ET-1 stimulates NRG1 mRNA expression) and by 
mechanical strain, which rises NRG1 expression151. 
NRGs bind to erythroblastic leukaemia viral oncogene homolog (ErbB) monomeric receptors, 
specifically to ErbB3 and ErbB4 (also known as human EGF receptor, HER3 and HER4). Ligand 
binding triggers these receptors and results in their dimerization. The receptor dimerization results 
in homodimers or heterodimers (with ErbB2), which activates signaling cascades, like the pathways 
of the mitogen-activated protein kinase (MAPK) and of the phosphatidylinositol-3-OH kinase 
(PI3K)/Akt. These pathways affect cell survival strategies and migration, proliferation, adhesion and 
differentiation properties150,152. 
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3.2. NRG1 and its receptors in the cardiovascular system 
In the heart, NRG1 is expressed and released by the endocardial and microvasculature 
endothelium. ErbB4 and ErbB2 are expressed in cardiomyocytes, while ErbB3 is expressed in 
mesenchymal cells of the endocardial cushion151,153,154. The differential expression of the solubilized 
ligand and receptors involves the paracrine transduction pathway associated with this signaling  axis 
in the heart151. The presence of different receptors in distinct cell types regulates the phenotypes 
observed in the various knockout (KO) models. The paracrine pathway through which NRG1 acts 
between cardiac EC and cardiomyocytes has been confirmed in co-culture studies151, pointing to 
the fact that NRG1 is a newly discovered contributor in cardiac endothelial–myocardial signaling, 
regulating the cardiovascular function155. 
3.2.1. NRG1/ErbB signaling and cardiac development 
The gene deletion studies in mice have demonstrate the role of the NRG1/ErbB system in cardiac 
trabelucation and myocardial development. NRG1 KO mice die during mid-embryogenesis as a 
consequence of the absence of normal trabeculation of the ventricles154. Also, ErbB2 or ErbB4 KO 
mice have a cardiac phenotype identical to NRG1 KO mice156,157. This cardiac phenotype seen in 
these gene mutants suggests the direct connection between ligand and receptor in the heart. It is 
suggested that NRG1 signaling needs ErbB2-ErbB4 heterodimers due to neither ErbB2 or ErbB4 
alone compensate the loss of the other receptor in the heart158. Moreover, ErbB3 KO mice exhibit 
cardiac cushion abnormalities, causing the reflux of blood through defective valves. This leads to 
embryo death, as shown for NRG1 KO and ErbB2 KO mice159. Besides that, in vitro NRG1 converts 
embryonic cardiomyocytes into cells of the conduction system160,161 and induces differentiation and 
survival of cardiomyocytes derived from embryonic stem cells162. Additionally, NRG1β/ErbB 
signaling regulates the ratio of nodal- to working-type cells in differentiating hESC-CM (human 
embryonic stem cell-derived cardiomyocytes) cultures and presumably functions equally through 
early human heart development163. 
3.2.2. NRG1/ErbB signaling in cardiac cellular responses 
Some in vitro studies performed with postnatal and adult cardiomyocytes have demonstrated that 
recombinant NRG1 administration promotes cell survival regulation164,165, hypertrophy, 
proliferation165,166, myofibrillar organization167 and cell-to-cell contact among cardiomyocytes168. 
NRG1 released from ECs protects cultured cardiomyocytes from apoptotic cell death induced by 
oxidative stress and anthracyclines164,169,170. NRG1 prevents cardiomyocyte apoptosis by inhibiting 
the release of cytochrome c and the activation of caspase-3 through a PI3K/Akt-dependent 
signaling pathway164,170. Furthermore, inhibition of ErbB2 and ErbB4 receptors leads to induction of 
Bcl-x splicing to its pro-apoptotic protein beta-adrenergic receptor, resulting in mitochondrial 
dysfunction and apoptosis171. Treatment of cultured adult rat ventricular myocytes with NRG1 
increases cardiomyocyte proliferation through ErbB4 signaling 172. In addition, NRG1 induces 
myocyte hypertrophy in an ErbB2-, 70-kDa protein kinase (p70S6K) and MAPK-dependent 
manner151,166. The NRG1 can also modulate the structure organization of cardiomyocyte. NRG1 
treatment induces cytoskeletal and sarcomeric organization166,168 and prevents myofibrillar 
disorganization in response to anthracycline damage167 (Fig. 3). 
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Figure 3 - NRG1/ErbB signaling in the cardiomyocyte. NRG1 regulates cardiomyocyte structure (a), function (b), growth, 
proliferation (c) and survival (d). (a) NRG1 stimulates myocyte lamellipodia formation and longitudinal elongation, in an 
ErbB2/FAK/Src-dependent way, enabling cellular adhesion and cell-to-cell contact between cardiomyocytes168. PI3K/Akt 
and ERK1/2 activation occur adjacently to the NRG1-stimulated sarcomeric organization, in healthy166 and cardiotoxic167 
situations. (b) eNOS activation, through NRG1/ErbB4-mediated Akt phosphorylation leads to an increase in NO 
production. NO can modulate exacerbated adrenergic stimulation (enhancing muscarinic receptor antiadrenergic 
actions)124 and activate PKG, which in turn phosphorylates PLN leading to increased SERCA2a activity and calcium uptake 
by the sarcoplasmic reticulum173. This contributes to improved cardiomyocyte function in healthy conditions, and in 
conditions with excessive b-adrenergic stimulation. In response to ischemic injury NRG1 leads to increased cMLCK 
expression and MLC-2v phosphorylation, improving cardiomyocyte functional recovery174. (c) NRG1/ErbB signaling  
induces protein synthesis and cardiomyocyte growth through ERK1/2 signaling 166. Differentiated, mononucleated 
cardiomyocytes can re-enter the cell cycle and proliferate in response to NRG1 stimulation172. Moreover, in conditions of 
ischemic injury, NRG1 can improve myocardial structure by decreasing hypertrophy172. (d) NRG1 protects cardiomyocytes 
from apoptosis in an ErbB/PI3K/Akt- dependent manner, by regulating Bcl-x splicing, cytochrome c release and capase-3 
activation164,170,171. Abbreviations: Akt, protein kinase B; B-AR, beta-adrenergic receptor; Bcl-xS/L, b-cell lymphoma xS/xL; 
cMLCK, cardiac myosin light chain kinase; cyt c, cytochrome c; eNOS, endothelial nitric oxide synthase; ErbB2/4, 
erythroblastic leukemia viral oncogene homolog 2/4; ERK1/2, extracellular signal-regulated kinases1/2; FAK, focal 
adhesion kinase; Gi, inhibitory guanine nucleotide binding protein; Gs, stimulatory guanine nucleotide binding protein; 
M2, muscarinic receptor; MLC-2v, myosin light chain 2v; PI3K, phosphoinositide-3- kinase; PKG, protein kinase G; PLN, 
phospholamban; SERCA2a, sarcoplasmic reticulum calcium ATPase; Src, proto-oncogene tyrosine-protein kinase. Adapted 
from Mendes-Ferreira et al.175. 
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3.2.3. NRG1/ErbB signaling in cardiac and vascular function 
Up-to-date experimental evidence reveals that NRG1 regulates myocardial performance and 
sympathovagal balance, suggesting that it is involved in hemodynamic homeostasis of the 
cardiovascular system. NRG1 desensitizes the cardiac muscle for the inotropic action of 
isoproterenol, providing modulatory feedback for the autonomic imbalance present in acute 
cardiac stress and in chronic HF176. This effect is dependent upon the activation of eNOS176. eNOS 
and β-adrenergic receptors are translocated to the caveolae, where eNOS attenuates adrenergic 
stimulation while increasing excitation–contraction coupling. Interestingly, ErbB receptors are co-
localized with eNOS in the caveolae177, allowing a better spatial relationship between NRG1 
activation of ErbB receptors, and a downstream signaling leading to its NO-mediated, anti-
adrenergic cardioprotective effects. Additionally, cardiomyocytes deficient in NRG1 signaling are 
unable to adequately counterbalance β-adrenergic activation by inhibitory parasympathetic 
activity178. This mechanism might contribute to the known increased risk of HF in injured human 
hearts where NRG1/ErbB signaling is suppressed. NRG1 acutely enhances NO production in adult 
ventricular myocytes through the activation of the PI3K/Akt pathway. The increase in NO leads to 
cGMP-dependent protein kinase (PKG) activation with the phosphorylation of phospholamban, 
which increases calcium uptake by the sarcoplasmic reticulum. This effect reveals an additional 
protective role of NRG1, through diastolic calcium handling173 (Fig. 3). 
Recent studies support a role for NRG1 in vascular function (Fig. 4). 
 
Figure 4 - NRG1 signaling in vessels. NRG1 is present in ECs and its release is increased in response to hypoxia133. 
However, there are contradictory results regarding the presence of ErbB receptors in ECs. Autocrine signaling (a) induces 
endothelial cell proliferation179. By contrast, later studies suggest that the effects of NRG1 on endothelial cell proliferation 
and angiogenesis are mediated through paracrine actions (b), via VEGF production180,181. Besides inducing EC proliferation 
and new vessel formation, NRG1 inhibits pathologic VSMC migration182 and foam cell formation, through decreased 
uptake of AcLDL and ACAT activity183, important mediators in the atherogenic process (c). Abbreviations: ACAT, acyl-
coenzyme A: cholesterol acyltransferase; AcLDL, acetylated low-density lipoprotein; EC, endothelial cell; ErbB2/4, 
erythroblastic leukemia viral oncogene homolog 2/4; ERK1/2, extracellular signal-regulated kinases1/2; PDGF, platelet-
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derived growth factor; SMC, smooth muscle cell; VEGF, vascular endothelial growth factor; VSMC, vascular smooth 
muscle cell. Adapted from Mendes-Ferreira et al.175. 
NRG1 is expressed in vascular ECs180 and stimulates angiogenesis in vitro (collagen gel tube 
formation) and in vivo (rat corneal angiogenesis and chick embryo chorioallantoic membrane 
models)179,181. NRG1 has a role in angiogenesis not only in normal physiologic conditions but also in 
response to tissue damage. NRG1 is required for proper angiogenesis and arteriogenesis during 
ischemic injury182. Additionally, NRG1 is expressed in atherosclerotic lesions184 and is associated 
with the inhibition of neointimal formation and mitogen-induced VSMC proliferation and migration 
after vascular injury185. These studies suggest that NRG1 could be a novel therapeutic candidate for 
the prevention of neointimal formation in diseases such as atherosclerosis and restenosis. 
 
3.2.4. NRG1/ErbB signaling in cardiovascular disease 
In vitro studies have demonstrated a central role for NRG1 in the modulation of cell survival, growth 
and integrity, as well as intrinsic myocardial performance. In vivo experiments emphasized the 
integrative role of NRG1/ErbB signaling in the response to several physiologic and pathophysiologic 
stimuli186. The premature development of dilated cardiomyopathy by pressure overload in 
NRG1/ErbB deficient mice187-189 suggest that, in vivo, NRG1 plays a protective function in the adult 
heart. Subsequent studies have reinforced the hypothesis that the NRG1/ErbB system is involved 
in the pathophysiology of several cardiac diseases, involving acute and/or chronic cardiac stresses. 
In response to acute ischemic damage, ventricular levels of NRG1 mRNA and protein, as well as 
phosphorylated ErbB4 receptors, are increased190. In endothelial cells, the deletion of NRG1 gene 
worsens ischemic injuries. The protective role of NRG1 in these conditions seems to be mediated 
by activation of cardiomyocyte eNOS176 through MAPK and Akt-dependent signaling 191. The 
activation of ErbB2 is required due to its role on cardiomyocyte proliferation and heart regeneration 
following myocardial infarction192. NRG1 also protects against doxorubicin (Dox)-induced cardiac 
toxicity. NRG1 and ErbB4 receptor knockouts show high sensibility to Dox treatment193,194, and Dox-
associated cardiomyocyte myofilament injury is increased when ErbB2 is inactivated151,167. NRG1 
also reduced Dox-induced alterations of excitation–contraction coupling and attenuated oxidative 
stress in adult rat cardiomyocytes195. 
NRG1/ErbB signaling could also have a function during chronic cardiac metabolic stress in diabetes 
and during development of diabetic cardiomyopathy (DCM). In rats with type 2 diabetes, ErbB 
receptor activation in the LV and delayed cardiac muscle relaxation is observed. These cardiac 
muscles perturbations are reversed when treated chronically with NRG, but without insulin196. 
Thereby, in DCM, it is observed the reduction of ErbB2 and ErbB4 receptor expression and 
phosphorylation, as well as of NRG1 protein synthesis197. 
During the development of HF induction occurs an increase of ErbB2 and ErbB4 receptor 
phosphorylation concurrently with an enhancement of NRG1 and metallopeptidase domain 19 
expression198. Also, an increased myocardial expression of NRG1 and ErbB4 phosphorylation is 
observed in the chronically stressed heart199. After experimental myocardial infarction, exercise 
training also results in increased NRG1 expression, as well as its downstream signaling 200. 
In left ventricular hypertrophy secondary to aortic stenosis, ErbB2 and ErbB4 levels are 
downregulated at the stage where the LV begins to fail201. NRG1 expression is increased during the 
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initial concentric hypertrophic phase. NRG1 levels decrease upon development of left ventricular 
dysfunction and eccentric left ventricular hypertrophy. These changes are possibly explained by 
increased neurohormonal activation151, which might be associated with decreased expression of 
both NRG1 and ErbB2 in the brainstem in animals with LV dysfunction secondary to aortic 
banding202. Administration of NRG1 directly into the brain prevented development of LV 
dysfunction and decreased noradrenaline excretion202.  
The animal studies propose that, in conditions of ventricular injury and dysfunction, activation of 
NRG1/ErbB signaling is part of an adaptive compensatory program that preserves cardiac function. 
In advanced stages of ventricular dysfunction, the activity of the NRG1/ErbB system is decreased. 
This maladaptive change is the result of reduced ventricular expression of NRG1, reduced 
expression of ErbB receptors and perhaps dysfunctional downstream ErbB signalling, Attenuation 
of compensatory NRG1/ErbB signaling could thus be an important event in the progression of HF.  
Various studies suggest that, as in animal models, NRG1 signaling has a protective function in the 
human heart, and loss of this pathway might induce HF. These observations have been derived from 
the cardiotoxic side effects of the chemotherapeutic agent trastuzumab (Herceptin1), a monoclonal 
antibody directed against ErbB2 used to treat receptor-positive breast carcinoma. Exposure to 
trastuzumab can induce a clinically significant cardiomyopathy that frequently reverses after 
therapy interruption203. These discoveries propose the possible interaction of the NRG1 pathway 
with the cardiovascular system and represent the vulnerability of heart to unexpected modulations 
of such signaling cascades204. In addition, NRG1 levels are increased and expression of ErbB2/ErbB4 
is decreased in ventricular tissue from patients with advanced HF. Curiously, these changes are 
reversed in patients with left ventricular unloading, due to a ventricular assist device205. 
A cohort of 899 patients with chronic HF showed an increase of NRG1 levels in serum, which 
correlates with disease severity (I–IV class of the New York Heart Association; NYHA), as well as risk 
of death or cardiac transplantation, identifying NRG1 as a possible biomarker of HF206. In addition, 
NRG1 expression by human macrophage foam cells was correlated with the progression of the 
atherosclerotic plaque183. Perik et al.207, in a study with 50 patients, found that serum levels of ErbB2 
were increased in patients with higher NYHA classes, lower left ventricular ejection fraction and 
higher levels of apoptosis-related cytokines. However, in a larger study, including 765 patients, 
ErbB2 serum levels were not associated with left ventricular end-diastolic pressure or ejection 
fraction208.  
3.2.5. NRG1/ErbB signaling in PAH glucose metabolism 
NRG1 pathway is also involved in the regulation of glucose metabolism. Indeed, acute treatment 
with NRG1 induces translocation of the GLUT4 to the plasma membrane and stimulates glucose 
uptake in L6E9 muscle cells and rat soleus209. NRG1 action on glucose uptake is mediated by a 
signaling cascade involving the PI3K-PDK1-PKCz pathway, and this effect is additive to that of 
insulin210. NRG1-induced glucose uptake has also been observed in adult rat ventricular myocytes, 
and it was associated with phosphorylation of Thr202/Tyr204 by ERK1/2 and of Ser473 by AKT153. 
The finding that NRG1-induced AKT phosphorylation at Ser473 can be blunted by pretreating 
cardiac myocytes with palmitate211 suggests that over-nutrition or hyperlipidemia could lead to 
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NRG1 resistance. Besides these acute short-term effects, incubation with NRG1 for 48h increases 
GLUT4 content in L6E9 muscle cells, suggesting that chronic NRG1 treatment could regulate muscle 
glucose metabolism and consequently systemic glucose homeostasis212. Conversely, NRG1 effects 
in liver, which also has a key role in glucose metabolism regulation213, have been less investigated. 
It has been reported that ERBB3 and, to a less extent, ERBB4 are expressed in liver of adult rats214-
216. Acute exposure of rat hepatocytes to NRG1 induces ERBB3 phosphorylation and activation of 
DNA synthesis217. Insulin seems to inhibit NRG1 action in rat hepatocytes. In two animal models of 
insulin deficiency (type I diabetes and fasting), liver ERBB3 expression is repressed following insulin 
treatment, suggesting an interaction between insulin and the NRG1/ERBB pathway216. 
Some studies evaluated the impact of NRG1 on glucose metabolism, in vivo. In vivo studies, a single 
injection of NRG1β was found to reduce blood glucose concentrations over 30–60 min and to 
increase blood glucose disposal over 60–90 min after treatment, as compared to vehicle treatment 
in diabetic mice. Glucose disposal was also increased after the NRG1β administration in diabetic 
mice218. Similarly, NRG1β was found to promote glucose disposal in normal and diabetic rats219. 
Consistent with these previous findings, Huang et al.220 revealed that cimaglermin alpha (CGF2), a 
full-length variant of NRG1β, reduces blood glucose concentrations in pigs and mice and increases 
blood glucose disposal in mice. These data are consistent with and further support the previous 
reports on NRG effects on glucose uptake, and clearly indicate that systemic administration of 
pharmacologic doses of NRG1β affect blood glucose handling in mice and pigs. 
The metabolic effects of NRG1 have not been completely clarified in the context of cardiovascular 
disease. So, further investigation of NRG1 effects on RV heart failure in PAH is deserved. 
3.2.6. Preclinical studies with NRG1 as a therapy for heart failure 
Several animal studies have shown the therapeutic effect of NRG1 in HF, with an improvement of 
cardiac performance, attenuation of disease markers and prolonged animal survival 172,174,190,221-224 
(Table 3). These positive effects of NRG1 treatment have been related with the following 
mechanisms: (i) cardiomyocyte replacement172; (ii) limitation of myocardial cell damage224; (iii) 
organization of sarcomeric structure174; (iv) reversal of ventricular remodeling223; (v) promotion of 
angiogenesis225; (vi) attenuation of mitochondrial dysfunction222; (vii) reduction of oxidative 
stress222; (viii) prevention of apoptosis225; (ix) modulation of myocardial calcium homeostasis195, and 
(x) attenuation of myocardial endoplasmic reticulum stress190. 
NRG1 attenuated pathologic alterations in experimental HF associated with numerous 
cardiovascular disorders224 by promoting sarcomere organization, decreasing myocardial cell 
damage and, thus, improving cardiomyocyte integrity and performance, leading to improved left 
ventricular function and decreased mortality224. Cardiomyocyte mitosis might play an important 
role in these structural changes once NRG1 induces mononucleated cardiomyocytes to divide172. 
Additionally, in vivo genetic inactivation of ErbB4 decreases cardiomyocyte proliferation, while 
increasing of ErbB4 expression enhances it. Injecting NRG1 in adult mice induces cardiomyocyte 
cell-cycle activity and promotes myocardial regeneration, causing the function improvement after 
myocardial infarction172, and lentiviral delivery carrying the human NRG1 gene injected into 
infarcted myocardium of rats, promoted angiogenesis and prevented apoptosis225. Encapsulation 
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of NRG1 in hydrogel administered directly to the infarcted myocardium border zone resulted in 
sustained and localized distribution, improving LV function through increased cardiomyocyte 
proliferation and decreased apoptosis226. Otherwise, association of NRG1 with microparticles 
results in a bioactivity increase for up to 12 weeks in rats with myocardial infarction227, and 
increases protein stability228, and administering these microparticles together with adipocyte-
derived stem cells resulted in decreased infarct size and improved LV function and remodeling229. 
Table 3 - Preclinical studies with NRG1 as a therapy for heart failure. 
Ref Model Treatment Outcome 
224 MI, rat 
10 mg/kg/day IV for 5 or 10 days, 1 week or 
2 months after LAD ligation 
Improved LV structure and function Decreased 
neurohumoral activation Improved survival 
172 MI, mouse 
2.5 mg/mouse IP for 12 weeks, 1 week after 
LAD 
Improved LV structure and function 
190 MI–I/R, rat 
1, 2, 4 or 8 mg/kg IV for 20 minutes prior to 
I/R 
Improved LV structure 
Decreased release of ischemia injury markers Decreased 
apoptosis 
174 MI, rat 
5 mg/kg/h IV for 7 days, 8 weeks after LAD 
ligation 
Improved LV structure and function through cMLCK 
upregulation 
222 MI, rat 
10 mg/kg/d IV for 10 days, 4 weeks after 
LAD ligation 
Improved LV structure and function 
Attenuation of mitochondrial dysfunction 
225 MI, rat 
Infarcted area injected with rhNRG1 
carrying lentivirus 
Decreased apoptosis and increased revascularization 
230 MI, pig 
0.67 – 2 mg/kg for 7 days after MI, and 
every 3 – 4 days, for a total of 8 doses (from 
day 7 to 35) 
Increased LV fractional shortening 
Decreased LV end-diastolic dimension 
Decreased fibrosis ultrastructure 
226 MI, mouse 
2.5 μg through 3 peri-infarct 
intramyocardial injections 
Increased LVEF 
Decreased LV area 
231 MI, rat 
0.65 – 3.25 mg/kg 2 weeks after MI for 10-
20 days with a washout period between 1 
and 4 weeks 
Increased LVEF 
190 MI-I/R, rat 4 μg/kg IV 20 minutes before I/R 
Decreased endoplasmic reticulum stress 
Decreased infarct size and apoptosis 
191 MI-I/R, mouse 80 ng/kg IP 5 minutes before I/R Decreased infarct size 
224 
Dox-induced 
CM, rat 
20 mg/kg/day IV for 5 days, 4 weeks after 
first doxorubicin administration 
Improved cardiac function and survival Decreased 
necrosis 
221 
Dox-induced 
CM, mouse 
0.75 mg/kg/day SC for 3–5 days (beginning 1 
day prior to dox administration) 
Improved cardiac function and survival 
Decreased myocardial injury markers 
223 DCM, rat 
10 mg/kg IV every 2 days for 2 weeks, 12 
weeks after streptozotocin injection 
Improved LV function 
Decreased apoptosis and fibrosis 
196 
DCM, apoE(-/-) 
mice 
20 μg/kg/day, 5 days/ week for 14 weeks in 
a preventive approach 
Improved LV function and remodeling 
Decreased the development of diabetic nephropathy 
224 
Myocarditis, 
mouse 
30 mg/kg/day IV for 5 days 
Improved LV structure, function and improved survival 
Decreased myocardial necrosis 
224 CRP, dog 
mg/kg/day IV for 5 days with continuous 
pacing, 3 weeks after the beginning of rapid 
pacing 
Improved cardiac function 
232 CLP, rat 10 μg/kg 30 minutes before CLP 
Improved survival 
Improved LV function 
Decreased myocardial inflammation 
Decreased expression of cardiac injury markers 
233 RIHD, rat 
15 μg/kg, 3 days before and 7 days after 
irradiation 
Decreased myocardial injury 
Improved LV function 
Decreased energetic dysfunction 
Improved cardiac structure 
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Abbreviations: apoE(-/-), apolipoprotein E knock-out; CM, cardiomyopathy; cMLCK, myosin light chain kinase; CLP, cecal 
ligation and puncture; CRP, chronic rapid pacing; DCM, diabetic cardiomyopathy;  Dox, doxorubicin; IP, intraperitoneal; 
IV, intravenous; I/R, ischemia/reperfusion; LAD, left anterior descending artery; LV, left ventricular; LVEF, left ventricle 
ejection fraction; MI, myocardial infarction; rhNRG1, recombinant human neuregulin-1; RIHD, radiation induced heart 
dysfunction; SC, subcutaneous. 
The same is observed when differentiating fibroblast-derived induced pluripotent stem cells into 
cardiomyocytes with NRG1234, or overexpressing ErbB4 in mesenchymal stem cells235, and 
delivering them into the infarcted or peri-infarct zones.  
Recently, administration of GGF2, which binds to ErbB4 receptor with high-affinity, increased LV 
function in animals with myocardial infarction, for up to a month after treatment withdrawal231. 
Probably, it represents a significant advantage when compared to the commonly used NRG1 
isoform containing the EGF domain. Other animal models also showed significant improvements 
using this isoform, suggesting that treatment with GGF2 might result in better outcomes230. 
Despite very promising, NRG1 stimulation of cardiomyocyte proliferation might be time-
dependent, where treatment with NRG1 at an early stage in mice with cryoinjury resulted in 
increased myocardial function and cardiomyocyte proliferation, compared to a late 
administration236. 
In a rat model of HF, NRG1 improved left ventricular remodeling and cardiac function in the failing 
heart, through the reduction of mitochondrial dysfunction, myocyte apoptosis and oxidative stress. 
In a DCM animal model, treatment with NRG1 also improved heart function, decreased apoptosis 
and reversed cardiac remodeling through decreased fibrotic tissue deposition223, and is able to 
decrease the development of diabetic nephropathy196. 
Interestingly, treating mice with rhNRG1 at a dose high enough to stimulate cardiac regeneration, 
for long periods of time (up to 211 days), did not result in any somatic, organ or neoplastic 
growth237, confirming the safety of this treatment. In addition, radiation induced myocardial injury, 
a secondary effect of antineoplastic treatment, is reduced by NRG1 treatment that is able to 
attenuate nuclear damage and maintain energetic homeostasis and cardiac function233. These 
findings validate the observation that inhibiting this pathway in patients undergoing chemotherapy 
might lead to cardiac dysfunction203. 
 
3.2.7. Clinical trials with recombinant NRG1 as a therapy for heart failure 
Recently reported clinical trials have demonstrated the effects of recombinant human NRG1 
(rhNRG1) in patients with stable chronic HF on optimal medical therapy238,239 . A Phase II trial, in 
which a daily intravenous infusion of rhNRG 1 was given to patients during 10 consecutive days, 
showed an increase in left ventricular function and structure observed at day 30 after the 10-day 
treatment. Interestingly, on day 90 structure and function were even further increased238. Another 
Phase II trial in which patients received a consecutive 12-hour intravenous infusion of rhNRG1 for 
10 days showed an increase in CO of 30% and a decrease in pulmonary artery wedge pressure and 
systemic vascular resistance of 30% and 20%, respectively. Twelve weeks post the 11 days of 
infusion, left ventricular ejection fraction showed a 12% increase239. Importantly, in these studies, 
the short-term rhNRG1 administration was safe and well tolerated. 
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Larger trials are now ongoing. A Phase II interventional clinical trial has set out to determine, over 
a period of 12 months, the efficacy and safety of NRG1 as a treatment in 120 patients with chronic 
HF (NCT01251406; http://www.clinicaltrials.gov), and has been finished, but no results have been 
published yet. The same research group also planned Phase III clinical trials with the purpose of 
evaluating the ability of NRG1 in reducing the death rate (NCT01541202; 
http://www.clinicaltrials.gov, status unknown according to ClinicalTrials.gov), cardiac remodeling 
(NCT01439893; http://www.clinicaltrials.gov, replaced by a another study with different endpoints) 
and efficacy and safety of its subcutaneous administration in patients with chronic HF 
(NCT01214096; http://www.clinicaltrials.gov, patient recruitment has been suspended, but no 
results have been posted yet). A Phase I clinical trial with GGF2, a NRG1 isoform, set out to 
determine its effects on patients with left ventricular dysfunction and symptomatic HF 
(NCT01258387; http://www.clinicaltrials.gov). The results have been published recently, and have 
suggested that a single intravenous dose of GGF2 improved LV ejection fraction over 90 days, while 
being well tolerated240. 
In summary, rhNRG1 is emerging as a promising treatment option for cardiovascular disease and 
left ventricular dysfunction. Disabled NRG1/ErbB signaling is implicated in the transition from 
compensatory hypertrophy to failure, whereas ErbB receptor activation promotes cardiac 
protection during acute cardiac injury and chronic ventricular remodeling. Recent clinical trials have 
shown that brief administration of rhNRG1 to humans is safe, well tolerated and results in apparent 
acute and sustained improvements in cardiac function in patients with stable chronic HF. The 
potential development of cancer during prolonged administration is a concern and will require 
attention. Also, a better understanding of the mechanisms by which the NRG1/ErbB system exerts 
protective cardiac effects is needed. 
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II – AIM AND OBJECTIVES 
 
In this thesis, we aimed to explore the metabolic mechanism underlying the beneficial effects of 
rhNRG1 in the treatment of PAH, in order to guide further molecular research in this context. 
 
Our specific goals are to: 
 
- Evaluate the gene expression of glucose transporters, specially GLUT1 and GLUT4 in the 
different degrees of the disease and correlate them with some PAH markers. 
 
- Evaluate the effect of chronic treatment with NRG1 on the expression of the same 
glucose transporter genes and to compare the molecular changes between animals with 
PAH and animals with PAH treated with rhNRG1. 
 
- Determine the effect of chronic treatment with NRG1 on the expression of some 
mitochondrial proteins, comparing the levels of these proteins in MCT animals and 
treated animals. 
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III - MATERIALS AND METHODS 
 
All the procedures in this work followed the recommendations of the Guide for the Care and Use 
of Laboratory Animals, published by the US National Institutes of Health (NIH Publication No. 85-
23, Revised 1996), and are accredited by the Portuguese Direção Geral de Alimentação e Veterinária 
(DGAV) and approved by Fundação para a Ciência e a Tecnologia (FCT PTDC/SAU-
FCT/100442/2008). 
1. Animal model 
Wistar male rats (Charles River Laboratories; Barcelona, Spain), weighting 180-200 g, were 
randomly assigned to receive either a subcutaneous injection of 60mg/kg BWT of MCT (Sigma 
Chemical) or an equivalent volume of vehicle (0.9% NaCl). Fourteen days after the first injection, 
animals were again randomly assigned into 4 subgroups according to pharmacological treatment: 
CTRL (animals without PAH and without pharmacological treatment, n=8); MCT (animals with PAH 
and without pharmacological treatment n=8); MCT+rhNRG1 (animals with PAH and with 
pharmacological treatment n=8); CTRL+rhNRG1 (animals without PAH and with pharmacological 
treatment, n=8). Pharmacological treatment consisted on a daily intraperitoneal injection of 
40μg/kg BWT of rhNRG1 (Peprotech, Germany) for 7 days, while the vehicle treatment consisted of 
0.1% Bovine Serum Albumin (BSA, Sigma-Aldrich) intraperitoneal injection for 7 days. 
Animals were grouped three per box, in a controlled environment, with a light-darkness cycle of 
12:12h, controlled temperature at 22ºC, and water and food ad libitum. Before MCT administration, 
an echocardiography evaluation was performed, to allow a basal evaluation to compare 
experimental groups and to prevent the inclusion of potential ill animals (cardiac pathology or 
other) in the next step of the protocol. Between 21 and 24 days after MCT administration, the 
animals were submitted again to echocardiographic evaluation and to invasive hemodynamic 
evaluation. After the morphometric evaluation of animals, tissue samples from different organs 
were collected and processed to histological and molecular biology studies.  
2. Protein expression  
4.2.1. RT-PCR  
Total RNA was extracted by using the method RNeasy Mini Kit (Quiagen, 74104) according to the 
instructions of the manufacturer. Concentration and purity of RNA were evaluated using the 
NanoDrop® ND-2000 spectrophotometer (Thermo Fisher Scientific). mRNA relative expression 
quantification was performed by two-step Real-Time Polymerase Chain Reaction (RT-PCR). Using 
RV samples from the CTRL group, standard curves were built to all the studied genes, correlating 
the initial total mRNA quantity and the threshold cycle. Reverse transcription was performed in a 
conventional thermocycler (Whatmann Biometra, 050-901) and consisted in 10 minutes at 22ºC, 
50 minutes at 50ºC, and 10 minutes at 95ºC. Ten percent of the obtained cDNA was amplified and 
detected by RT-PCR (Step-One™ Applied Biosystems), using the probes SYBR Green (PerfeCta® SYBR 
Green FastMix, Rox, Kit, Quanta Biosciences) according to the manufacturer instructions.  
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Amplification curves were analyzed with the equipment software (v2.2.2), through absolute 
quantification. Melting curves of each PCR reaction were used to exclude the formation of primer-
dimers and unspecific products, confirming the purity of the amplified product. GAPDH was chosen 
as reference gene, since no significant changes were observed in the different groups. Gene 
expression results were presented in Arbitrary Units (AU), being the CTRL group means values after 
GAPDH normalization correspondent to 1AU. All assays were performed twice. The primers used in 
the molecular analysis (see Table 4) were designed in-house with the appropriate software 
(DNAstar™). 
 
Table 4 - List of primers 
Gene Primers sequences 
 Forward Reverse 
GAPDH 5’TGG CCT TCC GTG TTC CTA CCC3’ 5’CCG CCT GCT TCA CCA CCT TCT3’ 
ET-1 5’CGG GGC TCT GTA GTC AAT GTG3’ 5’CCA TGC AGA AAG GCG AAT GTG3’ 
BNP 5’CAG AGC TGG GGA AAG AAG AG3’ 5’GGA CCA AGG CCC TAC AAA AGA3’ 
HIF-1α 5 ́TCA TAG GCG GTT TCT TGT AGC3’ 5’CTA ACA AGC CGG AGG AC3’ 
GLUT1 5’TCC TTA TTG CCC AGG TGT TC3’ 5’GCA GAA GGG CAA CAG GAT AC3’ 
GLUT4 5’ATA GCC CTT TTC CTT CCC AA3’ 5’AGG CAC CCT CAC TAC CCT TT3’ 
4.2.2. Western Blotting  
Frozen samples of RV were homogenized, on ice, in 1 mL RIPA lysis buffer (ThermoFisher Scientific), 
containing protease inhibitors (protease inhibitor cocktail, Sigma Chemical, St. Louis, MO), and 
phosphatase inhibitors (phosphatase inhibitor cocktail, Sigma Chemical, St. Louis, MO). 
Homogenates were centrifuged at 12,000 x g for 20 min at 4°C. Supernatants were collected, and 
total protein concentration was determined using the Bradford assay (Bio-Rad Laboratories, CA, 
USA). Protein aliquots (15 µg), diluted with Laemmli loading buffer (Cell Signaling Technology) 
containing β-mercaptoethanol (4:1), were loaded onto a 10% SDS-PAGE gel, run and electroblotted 
onto a 0,2 µm nitrocellulose membrane (Bio-Rad Laboratories, CA, USA). Pre-stained molecular 
weight marker proteins (Precision Plus ProteinTM Standards, Bio-Rad Laboratories, CA, USA) were 
used as size standards for the SDS-PAGE. Ponceau staining was performed to verify the quality of 
the transfer. Blots were blocked in 5% NFDM (Non-fat dry milk, Bio-Rad Laboratories, CA, USA) for 
1 hour at room temperature, and incubated overnight at 4ºC with primary antibody (Table 5) at a 
dilution of 1:500. 
Table 5 - List of primary antibodies 
Protein Antibody’s Identification 
GLUT4 GLUT4 (sc-53566), Mouse mAb, Santa Cruz Biotecnology, Inc. 
DRP-1 DRP-1 (sc-101270), Mouse mAb, Santa Cruz Biotecnology, Inc. 
OPA-1 OPA-1 (sc-393296), Mouse mAb, Santa Cruz Biotecnology, Inc. 
SOD1 SOD1 (sc-101523), Mouse mAb, Santa Cruz Biotecnology, Inc. 
SOD2 SOD2 (sc-130345), Mouse mAb, Santa Cruz Biotecnology, Inc. 
GAPDH GAPDH (0411), Mouse mAb, Santa Cruz Biotechnology, Inc. 
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Prior to incubation with secondary antibodies, nitrocellulose membranes were washed with TBS-T, 
containing Tris-buffered saline (Cell Signaling Technology) and 0.01% Tween solution (Sigma-
Aldrich, St. Louis, USA). All secondary antibodies (IRDye 680LT, Goat-anti-Mouse Ab and 800CW, 
Goat-anti-Mouse Ab, LI-COR Biosciences, Lincoln, USA) were applied in 5% NFDM at a 1:10000 
dilution for 1 hour at room temperature. After washing the membranes with TBS-T, membranes 
were scanned using an Odyssey scanner (infrared imaging system, LI-COR Biosciences, Lincoln, USA) 
and analyzed using the Odyssey provided software (version 3.0). Protein expression data are 
presented in Band Intensity (B.I.), being the CTRL group means values after GAPDH normalization 
correspondent to 1B.I. All assays were performed twice. 
3. Oral glucose tolerance tests and metabolic measurements 
Oral glucose tolerance tests (OGTTs) were performed at the first day of NRG1 injection and at the 
end of protocol. Rats were fasted overnight (12 hours) and OGTTs was performed glucose loading 
by gastric gavage (2 g/kg BWT). Blood glucose levels were determined, using a glucometer at the 
time of glucose loading (0), and then at 15, 30, 60, 90 and 120 min after loading (FreeStyle Precision 
Neo). OGTTS were repeated in the day of animal’s hemodynamic evaluation. 
4. Statistical analysis 
Statistical analysis was performed using GraphPad Software (vs.7). One-way ANOVA was used to 
statistically analysis these parameters. Group data are presented as means ± SEM. Differences with 
p<0.05 were considered statistically significant. 
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IV -RESULTS 
1. Characterization of GLUT1 and GLUT4 expression in the MCT model 
In order to characterize the GLUT1 and GLUT4 expression in MCT model, we divided the MCT-
induced PAH animals group in two subgroups, according to their RV ejection fraction (EF): 
compensated RV (CRV) and decompensated RV (DRV), and compared their mRNA levels with those 
of the control group (Fig. 5). 
The ejection fraction is an important measurement in determining how well heart is pumping out 
blood and in diagnosing and tracking HF (Fig. 5A). The CRV subgroup of MCT-induced PAH animals 
displayed an EF above of 35%, while the DRV subgroup was characterized by exhibiting EF values 
below 35%. We’ve found a significant difference (p<0.05) between the control group and both 
compensated and decompensated RV. Also, a significant difference between compensated and 
decompensated RV groups was verified. 
The analysis of the gene expression of ET-1 and brain natriuretic peptide (BNP) (Fig. 5B and 5C) gave 
us an indication of the state of overload and ventricular hypertrophy. The expression of HIF-1α (Fig. 
5D) gene was studied, once it’s involved in PAH metabolic dysfunction and RVH. In the DRV animals 
we’ve observed an increase in mRNA levels of ET-1 (Fig. 5B), BNP (Fig. 5C) and HIF-1α (Fig. 5D), 
when compared with the control group. However, no difference was observed between the CRV 
and control group.  
As described above, PAH has been associated with signaling pathways of the energy metabolism. 
Thereby, we’ve quantified the mRNA levels of the glucose transporters, GLUT1 and GLUT4. We 
verified an increase of GLUT1 gene expression in both MCT groups (Fig.5E). Conversely, the 
expression of GLUT4 gene was decreased in the DRV group(Fig.5F).  
 
 
Figure 5 - Characterization of GLUT1 and GLUT4 expression in the MCT model. The healthy animals were included in the 
control group (C) and MCT-induced PAH animals (MCT) were divided into compensated right ventricle group (CRV) and 
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decompensated right ventricle group (DRV). The percentage (%) of ejection fraction (EF) was evaluated by invasive 
hemodynamics (Panel A) and mRNA levels were determined by RT-PCR (Panels B-F). The dashed line in panel A assigns 
for 35% of EF. The expression levels of endothelin-1 (ET-1), brain natriuretic peptide (BNP), hypoxia-inducible factor 1-
alpha (HIF-1α), glucose transporter 1 (GLUT1) and glucose transporter 4 (GLUT4) are expressed in arbitrary units (AU), 
using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as reference gene. Bars represent mean+SEM of 8 rats per 
group. *P<0.05 vs. Control, #P<0.005 vs. CRV. One-way ANOVA was used for all the parameters presented. 
 
2. GLUT1 and GLUT 4 correlation with markers of disease  
After the characterization of GLUT1 and GLUT4 expression in the MCT model, we’ve determined 
the correlation between the expression of these genes and those of markers of disease (Fig. 6). 
We observed that EF values correlate negatively with mRNA levels of GLUT1 (Fig. 6A) and positively 
with mRNA levels of GLUT4 (Fig. 6B). 
As previous mentioned, HIF-1α has been associated with the induction of GLUT1 expression. 
Accordingly, when we compared GLUT1 expression with HIF-1α expression, we verified that exists 
a positive correlation between them, as shown in Fig. 6C. 
Conversely, when we related the expression of GLUT4 gene with the expression of both BNP and 
ET-1 genes we’ve found a negative correlation (Fig.6D and 6E, respectively).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 - GLUT1 and GLUT4 correlation with markers of disease. The correlation analysis was performed using the 
data displayed in Fig.5, which correspond to data obtained from animals that had mRNA quantification (AU, arbitrary 
units), using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as reference gene, and percentage (%) of ejection 
fraction (EF) analysis (•). Statistical analysis reveals significant correlation (r>0.05; p<0.005) between the expression of 
glucose transporter 1 (GLUT1) with EF (panel A) and the expression of hypoxia-inducible factor 1-alfa (HIF-1α) (panel 
C), as well as between the expression of glucose transporter 4 (GLUT4) with EF (panel B) and the expression of brain 
natriuretic peptide (BNP) (panel D) and endothelin-1 (ET-1) (panel E). 
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3. Effect of chronic treatment with rhNRG1 on the expression of GLUT1 and GLUT4 
In Fig. 7, we show the effect of chronic treatment with rhNRG1 on the expression of GLUT1 and 
GLUT4 in RV samples from the several experimental groups. We observed that GLUT4 gene 
expression was increased in all rhNRG1-treated animals when compared with the control group, 
but only the MCT+rhNRG1 (MN) group presents a significant difference. Although we observed a 
decreased expression of GLUT4 gene in the MCT group, this decline was not significant when 
compared with both control groups (Fig. 7A). 
In addition, we also noticed that the expression of GLUT1 gene was significantly increased on the 
MCT group, and the treatment with rhNRG1 attenuated the expression of this gene, as seen in Fig. 
7B.  
In the Fig. 7C, we show the results of grouping all the animals that belong to the MCT group. 
Thereby, we can observe that the ejection fraction was above 35%. In Fig. 7C, we can also observe 
that the treatment with rhNRG1 improved the ejection fraction of MCT animals significantly when 
compared with the MCT group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In Fig. 8, we showed that GLUT4 protein levels were greatly reduced in the diseased group relative 
to the other groups. Moreover, it was found that chronic administration of rhNRG1 to MCT animals 
induces a significant increase of the GLUT4 protein levels. Actually, the expression of GLUT4 gene 
at protein level in MN group and in control group are similar. 
 
 
 
 
 
 
 
 
 
 
* P<0.05 vs. C 
# P<0.05 vs. M 
Figure 7 - Effect of chronic treatment with NRG1 on the expression of GLUT1 and GLUT4. The experimental animals 
were divided in control group (C), control group treated with rhNRG1 (CN), MCT-induced PAH group (M) and M group 
treated with rhNRG1 (MN). The mRNA levels of glucose transporter 4 (GLUT4) and glucose transporter 1 (GLUT1) were 
determined by RT-PCR (Panels A and B) and the percentage (%) of ejection fraction (EF) was evaluated by invasive 
hemodynamics (Panel C). The dashed line in panel C assigns for 35% of EF. mRNA levels of GLUT4 and GLUT1 are 
expressed in arbitrary units (AU), using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as reference gene. *P<0.05 
vs. Control, #P<0.005 vs. M. One-way ANOVA was used for all the parameters presented. 
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4. Effect of chronic treatment with rhNRG1 on glucose tolerance 
As we demonstrated, the glucose transporters expression was altered in the diseased group, and 
the treatment with rhNRG1 attenuated the changes in their expression, in vitro. So, we decided to 
evaluate the impact of rhNRG1 on glucose metabolism, in vivo. For that, we performed OGTT. 
However, we did not find differences in glucose tolerance between study groups, as showed in Fig. 
9. 
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Figure 8 - Effect of NRG1 in the GLUT4 protein. The experimental animals were divided in control group (C), MCT-
induced PAH group (M) and M group treated with rhNRG1 (MN). The protein levels of glucose transporter 4 (GLUT4) 
was quantified by immunoblotting. The GLUT4 protein levels are expressed in band intensity (B.I.).  Bars represent 
mean+SEM of 4-5 rats per group. **P<0.05 vs. Control, ##P<0.005 vs. M. One-way ANOVA was used for all the 
parameters presented. The numbers on the left side of the representative gel assign to the molecular weights, in 
kilodaltons, of GLUT4 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), used as reference protein. 
Figure 9 - Effect of chronic treatment with rhNRG1 in glucose tolerance. 
Blood samples were collected from animals of control group (C; n=8), 
control group treated with rhNRG1 (CN; n=8), MCT-induced PAH group (M; 
n=8) and M group treated with rhNRG1 (MN; n=8), at different time points 
for measuring concentrations of glucose. Oral glucose tolerance is 
expressed as area under the curve (AUC) of oral glucose tolerance tests 
(OGTTs), in the four animal groups after subtracting baseline 
concentrations. Bars represent mean+SEM. 
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5. Effect of chronic treatment with NRG1 on the expression of mitochondrial proteins. 
To understand the effect of rhNRG1 treatment in metabolic dysfunction of the RV, and knowing 
that mitochondria play an important role in cells metabolism, we evaluated the protein levels of 
superoxide dismutase 2 (SOD2), once epigenetic silence of SOD2 results in HIF-1α activation and 
triggers redox changes in PAH. However, we found no differences in our study. In addition, we’ve 
also studied the protein levels of SOD1, a cytosolic superoxide dismutase which expression and 
activity are decreased in rats with MCT-induced PH. Once again, no significant differences in this 
protein was observed between studied groups. 
Finally, we evaluated dynamic related-protein 1 (DRP-1), the key mediator of mitochondrial fission, 
and optic atrophy 1 (OPA-1), an inner mitochondrion membrane GTPase, involved in mitochondrial 
fusion. Again, we’ve not found statistically significant differences between the experimental 
groups. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 110 - Effect of chronic treatment with rhNRG1 on the expression of mitochondrial proteins. The experimental 
animals were divided in control group (C), MCT-induced PAH group (M) and M group treated with rhNRG1 (MN). The 
protein levels of superoxide dismutase 1 (SOD1), superoxide dismutase 2 (SOD2), dynamic related-protein 1 (DRP1) and 
optic atrophy-1 (OPA1) were quantified by immunoblotting (Panels A-D). The protein levels are expressed in units of 
band intensity (B.I.). Bars represent mean+SEM of 4-5 rats per group. The numbers on the left side of the representative 
gel assign to the molecular weights, in kilodaltons, of DRP1, OPA1, SOD1, SOD2 and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), used as reference protein. 
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V -DISCUSSION 
1. PAH markers and glucose transporters expression are changed in the progression of RV 
hypertrophy. 
As known, right ventricular failure is the leading cause of death in patients with PAH140. Myocardial 
hypertrophy is a compensatory mechanism whereby cardiac tissue adapts to increased workload. 
Depending on the degree or duration of increased workload, ventricular hypertrophy may progress 
from a compensatory state to impaired systolic or diastolic function and HF. This transition is 
characterized by alterations in extracellular matrix composition, energy metabolism, β-adrenergic 
responsiveness, myofilament proteins, Ca2+ handling, signal transduction pathways, and gene 
expression profiles241.  
In this study, we divided MCT animals in two groups: (i) with an ejection fraction above 35% that 
presented a compensated RVH and (ii) MCT animals with an EF below 35% that showed a 
decompensate RVH. These findings are also concordant with the study of Hessel et al.241, where 
they characterized the right ventricular function after MCT-induced PAH in the rat with two 
different doses of MCT. They conclude that in the lower dose of MCT (30 mg/kg BWT), rats showed 
a compensatory RVH and a significant reduction of the ejection fraction, but when rats were treated 
with the higher dose (80 mg/kg BWT) presented a decompensated RVH and an EF much lower than 
the controls and rats injected with 30 mg/kg BWT of MCT.  
We’ve also analyzed cardiac overload and hypertrophy markers in PAH, such as ET-1 and BNP-1. 
BNP levels are associated with PAH242, its production is stimulated in response to pressure-
overload243 and is associated with the extent of RV dysfunction244, being increased in MCT-injected 
animals245. Plasma BNP is secreted mainly from the ventricles and correlates with cardiac indices in 
heart disease, showing a markedly increasing in decompensated HF246. Langenickel et al.247 
evaluated BNP mRNA in compensated and overt HF in both ventricles, concluding that ventricular 
BNP mRNA expression was not upregulated in any of the compensated HF models, whereas it 
increased in overt HF. These data indicate that cardiac BNP mRNA expression might be induced 
specifically in overt HF, pointing toward the possible role of BNP as a marker of the transition from 
compensated to overt HF. In our study we verified the same, an extreme increase of BNP gene 
expression in DRV group, but not in CRV group when both compared with control group. ET-1 
plasmatic levels are elevated in PAH, and associated with disease severity41. ET-1 is associated with 
the development of RVH in MCT-induced PAH248,249 and its expression is increased in this 
experimental model250,251. In our study, only the DRV group demonstrated an increase of ET-1 gene 
expression when compared with the study groups.  
As mentioned before, the RV when confronted with an increased oxygen requirement and/or a 
decreased oxygen supply, it is thought that hypertrophic RV tissue experiences higher degrees of 
hypoxia, resulting in the activation of transcription factors HIF-1143,144. As in the pulmonary 
vasculature, the activation of HIF-1 produces a glycolytic phenotype via up-regulation of glycolytic 
enzymes and suppression of glucose oxidation. Again, our studies are in agreement with the 
literature once we found that HIF-1α mRNA levels were only increased in the DRV group.   
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Hypertrophied hearts exhibit gene expression and metabolic profiles similar to that in fetal hearts, 
namely, increased reliance on glucose for fuel metabolism252. Since glucose has a higher oxygen 
efficiency for ATP production, the shift of substrate preference from fatty acid to glucose is 
therefore considered beneficial in the hypertrophied and failing myocardium253,254. However, 
“glucotoxicity” is observed in cardiomyocytes cultured in high glucose medium255-257, raising 
concerns whether adult cardiomyocytes in hypertrophied hearts can tolerate enhanced glucose 
uptake. In transgenic mice overexpressing insulin-independent glucose transporter GLUT1 in the 
heart (GLUT1-TG), the hearts have adapted to long-term increases in glucose usage without 
developing dysfunction even in the old age258. Moreover, the GLUT1-TG mice are protected from 
developing HF in pressure overload induced hypertrophy model as well as from 
ischemia/reperfusion injury258,259. Clinical studies 260,261 suggested that promoting glucose utilization 
in the hypertrophied and failing heart could be beneficial. However, a short-term induction of 
GLUT1 in cardiomyocytes at the onset of pressure overload-induced hypertrophy failed to improve 
contractile function despite the beneficial effects on mitochondrial function. Furthermore, 
researches have suggested that altered glucose metabolism in cardiac hypertrophy affects 
biological processes beyond energy generation259,262,263. A major change of glucose metabolism 
during cardiac hypertrophy is accelerated glycolysis. Increased rate of glucose uptake and glycolysis 
has been reported in multiple animal models of cardiac hypertrophy264-266. Upregulations of GLUT1 
expression have been observed in hypertrophied hearts both in vitro and in vivo. This finding 
coincided with our results, once we found that GLUT1 mRNA levels were increased in both stages 
of RVH when compared with control animals267. Although, the same was not observed for GLUT4 
mRNA levels. The GLUT4 gene expression was reduced only in a late phase of RV, corresponding to 
our DRV group. It was described that mRNA and protein levels of GLUT4 are decreased in 
hypertrophied hearts of both animal models and human patients and insulin stimulated glucose 
and uptake is only moderately affected, which it agreed with our findings267-270. Concluding it seems 
that the increase of glycolytic flux in cardiac hypertrophy is largely dependent upon a higher rate 
of insulin-independent glucose uptake. It has been proposed that activation of AMPK in the 
hypertrophied heart, as the consequence of impaired energetics, is responsible for promoting 
GLUTs translocation, enhancing glucose uptake and stimulating glycolysis by 
phosphorylation/activation of PFK2241,265,271,272.  
2. GLUT1 and GLUT4 correlate with markers of disease 
As explained before, GLUT1 and GLUT4 cardiac expression are related to the stage of RVH. The 
hypertrophied hearts act like a fetal heart, metabolically252. In embryonic and neonatal 
heart, GLUT1 is the predominant glucose transporter268. Our results showed a negative correlation 
between the EF and the expression of GLUT1 gene. However, the same was not verified for GLUT4 
gene expression, being the previous proportional to the EF. This result was concordant with 
literature in other pathophysiology contexts, where it was suggested that GLUT4 is rapidly 
upregulated only after birth while GLUT1 is downregulated. So, GLUT4 is the primary glucose 
transporter GLUT4 expressed in the postnatal and adult heart273,274. Also, GLUT4 has the same 
behavior with the EF and with the markers of hypertrophy and RV overload, being these three 
parameters indicators of RVH.   
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In our study, we concluded that GLUT1 gene expression was also positively correlated with RV HIF-
1α expression. Several studies, related to cancer275,276, have shown the same correlation between 
HIF-1α and GLUT1. They showed that tumor cells, like what happens to PAH lungs cells, shift of 
glucose metabolism from the more efficient oxidative phosphorylation to the less efficient 
glycolytic pathway, to maintain the energy production (the Warburg effect). For this reason, 
hypoxic cells tend to consume more glucose to meet their energy needs. HIF-1α mediates this 
metabolic conversion through the induction of enzymes involved in the glycolysis pathway and 
overexpression of GLUT1 which increase glucose import into tumor cells275,276. 
3. NRG1 treatment reverses changes in glucose transporters 
In the present study, RV GLUT1 mRNA expression was significantly increased in MCT animals, but 
the GLUT4 expression seems to be affected with the disease, although it was increased in all 
rhNRG1 animals. These results agree with previous studies146,209.  
Sivitz et al.277 investigated the mechanism by which cardiac glucose utilization increases during 
hypoxia and increased workload. They studied the effect of 2 and 14 days of hypobaric hypoxia on 
the cardiac expression of two subtypes of the facilitative D-glucose transporter, the GLUT4 or 
"insulin-regulatable" isoforms and the GLUT1 isoforms thought to mediate basal transport. Rats 
lost weight when exposed to hypobaric hypoxia, and developed RVH. RV GLUT1 mRNA levels 
increased compared with normal controls rats and RV GLUT4 mRNA decreased after hypobaric 
hypoxia. They conclude that hypobaric hypoxia increases cardiac GLUT1 expression and reduces 
GLUT4 expression early in the development of RVH. 
GLUT4 plays a key role in glucose uptake and metabolism in insulin target tissues. Being a rate-
limiting step in glucose metabolism, the expression and function of the GLUT4 isoform has been 
extensively studied and found to be tightly regulated at both mRNA and protein levels. Adaptation 
to states of enhanced metabolic demand is associated with increased glucose metabolism and 
GLUT4 gene expression278. In patients with HF, GLUT4 protein reduction is present and is related to 
disease severity, contributing to insulin resistance and energy metabolism modification. The 
reduction in GLUT4 protein may contribute to metabolic imbalance in this disease279. 
As mentioned, in vivo studies showed that a single injection of NRG1β was found to reduce blood 
glucose concentrations over 30–60 min and to increase blood glucose disposal over 60–90 min after 
treatment, as compared to vehicle treatment in diabetic mice. Glucose disposal was also increased 
after the NRG1β administration in diabetic mice218. In this work, we also tried to show the influence 
of the NRG1 treatment on glucose metabolism, in vivo, in blood samples of animal with PAH induced 
by MCT. Unfortunately, we did not find differences in glucose tolerance in all study groups. Possible 
explanations for these results are the heterogeneity of MCT model and the small number of 
experimental animals.   
4. NRG1 treatment on the expression of mitochondrial proteins 
In the vasculature, it was observed that metabolic changes appear to be triggered by changes in 
redox state that activate transcription factors, such as HIF‑1.  These redox changes in PAH include 
epigenetic silencing of SOD2 and/or changes in mitochondrial fission/fusion. Mitochondria in PAH 
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are deficient in complex I expression and SOD2 and their membrane potential is hyperpolarized50. 
These changes in the mitochondria create a “pseudohypoxic” redox milieu PASMC’s, in which local 
PO2 and the production of ROS are dissociated280. The consequence of this redox disorder is 
normoxic activation of HIF‑1α, both in experimental50, and human PAH50,281,282. This pathological 
HIF‑1 activation contributes to the aerobic glycolysis. HIF-1α activation can result from the redox 
changes initiated by epigenetic silencing of SOD2 in PAH283, consistent with prior descriptions of 
redox-regulation of HIF-1α284,285. Activated HIF-1α suppresses mitochondrial oxidative metabolism 
(by increasing the expression of pyruvate dehydrogenase kinases, PDKs, thereby blocking pyruvate 
uptake into the Krebs cycle)286 while simultaneously upregulating enzymes and transporters that 
favor glycolysis (hexokinase-2 and GLUT1). Targeting these mitochondrial metabolic abnormalities 
in PAH, using the PDK inhibitor dichloroacetate, reduces glycolysis, restores oxidative metabolism 
and regresses PAH in several experimental models287.  
In addition, SOD1 expression and activity are decreased in rat lungs with MCT-induced PAH, which 
is associated with increased markers of oxidative stress and decreased total antioxidant capacity 
despite enhanced SOD2 expression288. 
As mentioned the redox changes in PAH include alterations in mitochondrial fission, consequently 
DRP-1 expression is altered, since it is the key mediator of mitochondrial fission287. The expression 
and activity of DRP‑1 is increased in human PAH. Inhibition of mitochondrial fission, using the small 
molecular inhibitor of DRP1 arrests PAH PASMC in the G2/M phase of the cell cycle. This indicates 
that mitochondrial fission is a mitotic checkpoint. In human and experimental PAH, excessive 
activation of the GTPase DRP‑1 promotes excessive fission. HIF‑1α promotes fission by activating 
DRP‑1. HIF‑1α activation can be stimulated by administration of cobalt, and within two hours this 
fragments the mitochondrial network through a DRP‑1‑dependent mechanism. In vivo, 
administration of cobalt leads to a form of PAH287.  Mitochondrial fusion is decreased in PAH, and 
is mediated by large GTPases, mitofusin-1 and mitofusin-2, which reside in the outer mitochondrial 
membrane, and a GTPase called optic atrophy-1 (OPA-1), in the inner mitochondria membrane289.  
  
However, our study didn’t show any significant difference between experimental groups 
concerning the expression of these mitochondrial proteins. Once again, these results may be caused 
by a small sample number, being necessary to increase the number of study animals. Also, these 
results can reflect the variability of the MCT model.  
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VI-CONCLUSION 
 
In the present study, we observed that the expression of GLUT1 is associated with the development 
of the disease whereas GLUT4 is affected by chronic treatment with rhNRG1. The expression of 
GLUT1 and 4 correlates with parameters of cardiac function and with disease markers and chronic 
treatment with rhNRG1 attenuates the changes in GLUTs observed in MCT-induced PAH. This was 
to our knowledge the first study exploring the effects of NRG1 treatment in the expression of 
glucose transporters and in glucose tolerance in the context of PAH. We conclude that the 
therapeutic effects of rhNRG1 in PAH might be due, at least in part, to the regulation of GLUT1 and 
4 expressions. 
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